Top 10 Challenges in Cancer Immunotherapy

Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define...

Full description

Saved in:

Bibliographic Details
Published in	Immunity (Cambridge, Mass.) Vol. 52; no. 1; pp. 17 - 35
Main Authors	Hegde, Priti S., Chen, Daniel S.
Format	Journal Article
Language	English
Published	United States Elsevier Inc 14.01.2020 Elsevier Limited
Subjects	adaptive immune resistance Antigens Biology biomarkers bispecific antibodies Cancer cancer immune phenotypes Cancer immunotherapy CAR T cellular therapy Clinical trials Collaboration Cytotoxicity Drug dosages Humans Immune system immuno-oncology Immunology Immunotherapy Immunotherapy - methods intrinsic immune resistance Models, Biological Mutation Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy Patients primary immune escape secondary immune escape synthetic immunity T cell engagers Tumor Microenvironment - immunology tumor mutational burden Tumors intrinsic immune resistance biomarkers CAR T adaptive immune resistance cellular therapy primary immune escape cancer immune phenotypes tumor mutational burden secondary immune escape cancer immunotherapy synthetic immunity T cell engagers immuno-oncology bispecific antibodies
Online Access	Get full text

Cover

Loading…

Abstract	Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer. In recent years, cancer immunotherapy has become a pillar in the treatment of cancer. Hegde and Chen discuss the top ten challenges facing this field, including the opportunity to optimize both synthetic and endogenous immune approaches and to target different immune suppressive mechanisms specific for each patient with cancer.
AbstractList	Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer.Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer. Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer. In recent years, cancer immunotherapy has become a pillar in the treatment of cancer. Hegde and Chen discuss the top ten challenges facing this field, including the opportunity to optimize both synthetic and endogenous immune approaches and to target different immune suppressive mechanisms specific for each patient with cancer. Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer. SummaryCancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer.
Author	Hegde, Priti S. Chen, Daniel S.
Author_xml	– sequence: 1 givenname: Priti S. surname: Hegde fullname: Hegde, Priti S. organization: Genentech Inc., South San Francisco, CA, USA – sequence: 2 givenname: Daniel S. orcidid: 0000-0001-5085-3579 surname: Chen fullname: Chen, Daniel S. email: dschen@igmbio.com organization: IGM Biosciences, Mountain View, CA, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31940268$$D View this record in MEDLINE/PubMed
BookMark	eNqFkE1P3DAQhq0KVGDbf4BQpF7oIcHjjyTuoRJatYC0Ehd6trzOpHiV2IudVOLf42jhwoGeZiQ_7-vRc0aOfPBIyDnQCijUV7vKjePsXcUoqApYRQE-kVOgqikFtPRo2RtRNjXwE3KW0o5SEFLRz-SEgxKU1e0p-f4Q9gXQYv1ohgH9X0yF88XaeIuxuFs-CNMjRrN__kKOezMk_Po6V-TP718P69tyc39zt77elFbweiqRNQCslyhE31m15Q1uWwm9otK2HXI0Xdsjs9KyJj-ZLe3ywmXN2lZ1suErcnno3cfwNGOa9OiSxWEwHsOcNONcNYqJVmb02zt0F-bo83ULlSGZR6YuXql5O2Kn99GNJj7rNwkZ-HEAbAwpRey1dZOZXPBTNG7QQPViXO_0wbhejGtgOhvPYfEu_Nb_n9jPQwyzyn8Oo07WYbbeuYh20l1wHxe8ANbImao
CitedBy_id	crossref_primary_10_1126_sciadv_add6626 crossref_primary_10_3390_cancers13020319 crossref_primary_10_3389_fonc_2022_895103 crossref_primary_10_1002_adfm_202100386 crossref_primary_10_1038_s12276_022_00896_9 crossref_primary_10_1002_adma_202308924 crossref_primary_10_1016_j_modpat_2024_100624 crossref_primary_10_1186_s40001_024_01678_x crossref_primary_10_1016_j_cmet_2023_04_017 crossref_primary_10_1016_j_critrevonc_2021_103464 crossref_primary_10_1016_j_critrevonc_2025_104683 crossref_primary_10_1002_psp4_12693 crossref_primary_10_1038_s12276_024_01317_9 crossref_primary_10_3389_fcvm_2020_598384 crossref_primary_10_1038_s41586_020_2746_2 crossref_primary_10_1111_imr_12982 crossref_primary_10_2139_ssrn_4133124 crossref_primary_10_1016_j_ceca_2023_102803 crossref_primary_10_1038_s41467_022_29205_8 crossref_primary_10_1016_j_ucl_2020_10_005 crossref_primary_10_3389_fgene_2022_1066347 crossref_primary_10_1038_s41388_025_03273_8 crossref_primary_10_3390_diagnostics13061015 crossref_primary_10_52711_2231_5691_2022_00005 crossref_primary_10_1002_jcp_30018 crossref_primary_10_1016_j_hbpd_2022_07_006 crossref_primary_10_1016_j_iotech_2024_101040 crossref_primary_10_1002_anie_202004206 crossref_primary_10_1016_j_ejmech_2022_115064 crossref_primary_10_1136_jitc_2020_001046 crossref_primary_10_1136_jitc_2021_002434 crossref_primary_10_3389_fimmu_2024_1382576 crossref_primary_10_1136_jitc_2023_007447 crossref_primary_10_1016_j_critrevonc_2025_104691 crossref_primary_10_1038_s41392_020_00221_8 crossref_primary_10_3389_fonc_2022_902190 crossref_primary_10_1016_j_bbrc_2025_151394 crossref_primary_10_1039_D2BM01715F crossref_primary_10_2217_imt_2022_0140 crossref_primary_10_1039_D0BM01158D crossref_primary_10_3389_fimmu_2022_869297 crossref_primary_10_1038_s41467_022_29401_6 crossref_primary_10_1136_jitc_2023_007440 crossref_primary_10_3389_fonc_2021_670313 crossref_primary_10_1016_j_biomaterials_2024_122710 crossref_primary_10_1038_s41588_022_01108_w crossref_primary_10_1002_adma_202415078 crossref_primary_10_1016_j_ejmech_2023_115599 crossref_primary_10_1016_j_bbcan_2023_188961 crossref_primary_10_3389_fimmu_2021_758004 crossref_primary_10_1038_s41598_023_44777_1 crossref_primary_10_1016_j_ajpath_2024_07_015 crossref_primary_10_1007_s13402_023_00808_7 crossref_primary_10_1136_jitc_2023_007218 crossref_primary_10_1038_s41416_022_02076_y crossref_primary_10_1136_gutjnl_2022_326928 crossref_primary_10_1038_s41598_023_42541_z crossref_primary_10_1002_smtd_202201518 crossref_primary_10_3389_fcell_2022_818416 crossref_primary_10_4236_ijcm_2022_131004 crossref_primary_10_1016_j_intimp_2022_108727 crossref_primary_10_1016_j_bbcan_2024_189084 crossref_primary_10_1038_s41598_020_66902_0 crossref_primary_10_61186_ijrr_21_3_513 crossref_primary_10_1002_ctd2_109 crossref_primary_10_1038_s41556_024_01462_3 crossref_primary_10_1186_s12885_023_10959_3 crossref_primary_10_1002_advs_202301339 crossref_primary_10_1002_mog2_29 crossref_primary_10_1136_jitc_2020_002114 crossref_primary_10_2139_ssrn_4065598 crossref_primary_10_1002_smtd_202301332 crossref_primary_10_1016_j_apsb_2021_09_001 crossref_primary_10_3389_fimmu_2022_986214 crossref_primary_10_3390_cancers13051044 crossref_primary_10_1016_j_jare_2023_01_011 crossref_primary_10_3389_fimmu_2024_1424261 crossref_primary_10_1111_pin_13060 crossref_primary_10_3389_fimmu_2022_1009709 crossref_primary_10_3389_fimmu_2024_1452303 crossref_primary_10_3389_fimmu_2021_677169 crossref_primary_10_1002_adhm_202202064 crossref_primary_10_1016_j_biopha_2024_117298 crossref_primary_10_3389_fimmu_2023_1196970 crossref_primary_10_1016_j_bioactmat_2022_01_020 crossref_primary_10_1007_s10238_023_01240_9 crossref_primary_10_1021_jacs_2c10757 crossref_primary_10_1007_s11523_021_00810_9 crossref_primary_10_3389_fonc_2021_672928 crossref_primary_10_3390_jpm13030526 crossref_primary_10_3389_fimmu_2022_1011617 crossref_primary_10_1007_s00259_022_05903_9 crossref_primary_10_1142_S0218127424500159 crossref_primary_10_1016_j_omtn_2023_03_007 crossref_primary_10_3389_fimmu_2024_1454730 crossref_primary_10_1002_path_6290 crossref_primary_10_1016_j_fct_2023_113654 crossref_primary_10_1186_s13046_021_02111_5 crossref_primary_10_1038_s41577_023_00896_4 crossref_primary_10_3389_fped_2021_784024 crossref_primary_10_1002_adfm_202100354 crossref_primary_10_21518_2079_701X_2021_20_18_23 crossref_primary_10_3724_abbs_2022141 crossref_primary_10_1002_smll_202201298 crossref_primary_10_1093_abt_tbaa012 crossref_primary_10_1186_s43556_024_00225_8 crossref_primary_10_1038_s41418_023_01229_7 crossref_primary_10_1021_jacs_4c09831 crossref_primary_10_3889_oamjms_2021_6955 crossref_primary_10_1002_ctd2_70001 crossref_primary_10_1016_j_ctro_2020_12_006 crossref_primary_10_3390_ijms22179414 crossref_primary_10_1096_fj_202101548RR crossref_primary_10_1007_s12033_024_01348_7 crossref_primary_10_2147_JIR_S509316 crossref_primary_10_1002_advs_202305769 crossref_primary_10_1093_bib_bbaa345 crossref_primary_10_1186_s12575_023_00201_6 crossref_primary_10_1016_j_isci_2023_108198 crossref_primary_10_1021_acsanm_4c00890 crossref_primary_10_1038_s41598_024_53489_z crossref_primary_10_1111_jcmm_16907 crossref_primary_10_1038_s41419_024_07098_3 crossref_primary_10_2174_1871530321666210708142815 crossref_primary_10_1016_j_matt_2023_08_001 crossref_primary_10_3389_fimmu_2022_944898 crossref_primary_10_1007_s00109_022_02193_4 crossref_primary_10_18632_aging_103868 crossref_primary_10_1038_s41590_024_01943_5 crossref_primary_10_1002_adma_202417422 crossref_primary_10_1016_j_canlet_2024_217361 crossref_primary_10_1080_20479700_2023_2284464 crossref_primary_10_1021_acs_nanolett_1c01048 crossref_primary_10_1007_s10238_024_01328_w crossref_primary_10_1016_j_xcrm_2024_101879 crossref_primary_10_1007_s13105_024_01020_3 crossref_primary_10_1016_j_biomaterials_2021_120724 crossref_primary_10_3390_cells12081165 crossref_primary_10_1039_D0LC01305F crossref_primary_10_1016_j_ccr_2024_216207 crossref_primary_10_1016_j_actbio_2025_01_038 crossref_primary_10_1158_2159_8290_CD_20_1808 crossref_primary_10_1038_s41568_021_00431_4 crossref_primary_10_1186_s12943_024_02113_9 crossref_primary_10_1002_smtd_202300204 crossref_primary_10_3389_fimmu_2023_1169588 crossref_primary_10_1007_s00203_025_04267_6 crossref_primary_10_1016_j_ctarc_2024_100807 crossref_primary_10_2174_0115680096250376231025062652 crossref_primary_10_1002_jmr_2939 crossref_primary_10_1136_jitc_2021_002614 crossref_primary_10_3390_ijtm4010003 crossref_primary_10_2139_ssrn_4006148 crossref_primary_10_1016_j_ymthe_2024_03_023 crossref_primary_10_3389_fonc_2020_626555 crossref_primary_10_3390_cancers16040713 crossref_primary_10_1016_j_semcancer_2021_05_005 crossref_primary_10_3390_ijms21165845 crossref_primary_10_3389_fimmu_2022_807840 crossref_primary_10_1016_j_lfs_2023_122360 crossref_primary_10_3390_pharmaceutics14010070 crossref_primary_10_1002_mog2_62 crossref_primary_10_1042_BSR20202962 crossref_primary_10_1002_INMD_20230002 crossref_primary_10_1002_cam4_6869 crossref_primary_10_1021_acsnano_2c02605 crossref_primary_10_3389_fimmu_2020_620166 crossref_primary_10_1016_j_jconrel_2023_08_049 crossref_primary_10_1667_RADE_24_00098_1 crossref_primary_10_1002_cti2_1400 crossref_primary_10_1186_s12859_023_05268_2 crossref_primary_10_1093_bib_bbaa317 crossref_primary_10_1016_j_nantod_2021_101144 crossref_primary_10_1016_j_omtn_2022_08_021 crossref_primary_10_1016_j_nantod_2022_101661 crossref_primary_10_1186_s40364_023_00478_5 crossref_primary_10_1158_2326_6066_CIR_20_0586 crossref_primary_10_1186_s12885_022_09984_5 crossref_primary_10_1016_j_bcp_2021_114487 crossref_primary_10_1158_1055_9965_EPI_21_1334 crossref_primary_10_1186_s40364_020_00198_0 crossref_primary_10_1007_s12094_023_03145_1 crossref_primary_10_3389_fimmu_2022_1055235 crossref_primary_10_1016_j_imbio_2022_152181 crossref_primary_10_1021_acsami_4c05714 crossref_primary_10_1186_s13046_021_02133_z crossref_primary_10_1021_acsmacrolett_2c00742 crossref_primary_10_1016_j_jhep_2024_05_037 crossref_primary_10_1007_s13346_021_00923_8 crossref_primary_10_1155_2020_5825401 crossref_primary_10_3390_diagnostics13020302 crossref_primary_10_1186_s12859_023_05235_x crossref_primary_10_3389_fonc_2024_1406244 crossref_primary_10_3390_biomedicines10051074 crossref_primary_10_1016_j_biopha_2024_117426 crossref_primary_10_1016_j_ccr_2024_216069 crossref_primary_10_3389_fonc_2023_1140103 crossref_primary_10_1097_MD_0000000000038651 crossref_primary_10_1097_PPO_0000000000000466 crossref_primary_10_1038_s41467_022_31713_6 crossref_primary_10_1080_07357907_2024_2361295 crossref_primary_10_2147_IJN_S480799 crossref_primary_10_3390_cancers17010022 crossref_primary_10_1016_j_breast_2025_103876 crossref_primary_10_2217_imt_2022_0305 crossref_primary_10_3389_fphar_2023_1277902 crossref_primary_10_1126_scitranslmed_abd8836 crossref_primary_10_2174_1871530323666230213121803 crossref_primary_10_1002_ctm2_1315 crossref_primary_10_1016_j_envres_2023_117522 crossref_primary_10_1186_s12916_022_02315_2 crossref_primary_10_3389_fgene_2022_830793 crossref_primary_10_2174_0115733947273426231128054645 crossref_primary_10_1016_j_freeradbiomed_2022_10_004 crossref_primary_10_3390_biomedicines10020323 crossref_primary_10_3390_jcm11247523 crossref_primary_10_1016_j_jconrel_2021_12_003 crossref_primary_10_1016_j_molimm_2020_11_002 crossref_primary_10_1186_s13045_022_01363_8 crossref_primary_10_3389_fimmu_2022_941189 crossref_primary_10_1002_cam4_4221 crossref_primary_10_2147_IJN_S317220 crossref_primary_10_1007_s12185_022_03424_7 crossref_primary_10_3389_fimmu_2024_1384121 crossref_primary_10_1158_2326_6066_CIR_21_1075 crossref_primary_10_1002_adfm_202416406 crossref_primary_10_3390_diagnostics13132175 crossref_primary_10_1016_j_clim_2023_109685 crossref_primary_10_1089_ars_2022_0035 crossref_primary_10_3390_cancers15010196 crossref_primary_10_3390_cells10051006 crossref_primary_10_3389_fonc_2020_575737 crossref_primary_10_1016_j_jbc_2024_107447 crossref_primary_10_1111_1759_7714_13597 crossref_primary_10_1111_cpr_13283 crossref_primary_10_1136_jitc_2022_004973 crossref_primary_10_3390_ph14100993 crossref_primary_10_1016_j_canlet_2024_216858 crossref_primary_10_1039_D2NH00214K crossref_primary_10_3389_fonc_2021_768222 crossref_primary_10_1016_j_clim_2022_109163 crossref_primary_10_1038_s41598_024_52153_w crossref_primary_10_3389_fimmu_2022_998266 crossref_primary_10_1016_j_ccr_2022_214788 crossref_primary_10_1016_j_canlet_2024_216857 crossref_primary_10_1021_acsapm_1c01760 crossref_primary_10_3389_fmolb_2021_755911 crossref_primary_10_1016_j_biopha_2024_116317 crossref_primary_10_1007_s00262_024_03777_4 crossref_primary_10_1007_s44178_023_00028_x crossref_primary_10_3233_CBM_230036 crossref_primary_10_1016_j_ejca_2023_02_012 crossref_primary_10_1016_j_medp_2024_100006 crossref_primary_10_1017_erm_2021_26 crossref_primary_10_1136_jitc_2024_010528 crossref_primary_10_1002_adfm_202302825 crossref_primary_10_1038_s41388_023_02637_2 crossref_primary_10_1002_ange_202008083 crossref_primary_10_1186_s13045_024_01535_8 crossref_primary_10_1002_cac2_12183 crossref_primary_10_1002_INMD_20230047 crossref_primary_10_1186_s12920_023_01727_0 crossref_primary_10_1016_j_biopha_2021_112558 crossref_primary_10_1021_acsanm_4c04391 crossref_primary_10_1039_D2CS00247G crossref_primary_10_1172_JCI143296 crossref_primary_10_1002_tcr_202400010 crossref_primary_10_1016_j_addr_2022_114585 crossref_primary_10_1002_adfm_202309447 crossref_primary_10_1007_s00428_021_03256_6 crossref_primary_10_1186_s13578_023_01135_y crossref_primary_10_1016_j_addr_2021_05_001 crossref_primary_10_1155_2021_8970173 crossref_primary_10_1016_j_nantod_2022_101461 crossref_primary_10_1186_s12951_022_01561_z crossref_primary_10_15252_embr_202255532 crossref_primary_10_1126_sciadv_adh9547 crossref_primary_10_7759_cureus_30856 crossref_primary_10_1038_s41525_021_00202_y crossref_primary_10_3389_fimmu_2020_604967 crossref_primary_10_1038_s41419_022_05211_y crossref_primary_10_1126_sciadv_abc7828 crossref_primary_10_1360_TB_2021_0987 crossref_primary_10_62347_TYLL7952 crossref_primary_10_1002_advs_202203298 crossref_primary_10_1038_s41467_022_32080_y crossref_primary_10_1038_s41568_022_00454_5 crossref_primary_10_14218_JCTH_2020_00132 crossref_primary_10_1016_j_cclet_2021_10_074 crossref_primary_10_3233_CBM_230489 crossref_primary_10_1016_j_canlet_2024_216676 crossref_primary_10_3390_cancers14184439 crossref_primary_10_1016_j_apsb_2021_09_021 crossref_primary_10_1016_j_canlet_2020_03_024 crossref_primary_10_1126_sciimmunol_abq2424 crossref_primary_10_3390_cancers14184438 crossref_primary_10_1186_s12920_023_01509_8 crossref_primary_10_1016_j_nantod_2023_101992 crossref_primary_10_18632_aging_205637 crossref_primary_10_3389_fonc_2022_911572 crossref_primary_10_1007_s00262_021_02897_5 crossref_primary_10_2967_jnumed_123_266002 crossref_primary_10_3389_fgene_2022_876588 crossref_primary_10_1038_s41467_023_42332_0 crossref_primary_10_2217_nnm_2023_0202 crossref_primary_10_1016_j_jconrel_2023_08_022 crossref_primary_10_18632_aging_205848 crossref_primary_10_3390_molecules29010031 crossref_primary_10_3390_medicina60081270 crossref_primary_10_1016_j_ijbiomac_2022_11_253 crossref_primary_10_3389_fimmu_2021_693609 crossref_primary_10_1002_adhm_202301232 crossref_primary_10_3390_ijms232315155 crossref_primary_10_1186_s13046_023_02645_w crossref_primary_10_3389_fmolb_2020_599475 crossref_primary_10_3389_fonc_2021_673199 crossref_primary_10_1002_cai2_75 crossref_primary_10_3390_ijms222111781 crossref_primary_10_1002_cac2_12178 crossref_primary_10_1038_s41416_020_01225_5 crossref_primary_10_1080_07357907_2022_2092635 crossref_primary_10_1002_ctm2_1508 crossref_primary_10_1158_1078_0432_CCR_20_0245 crossref_primary_10_1158_0008_5472_CAN_23_0230 crossref_primary_10_1038_s41467_021_27750_2 crossref_primary_10_1111_cas_15537 crossref_primary_10_1016_j_canlet_2023_216596 crossref_primary_10_1186_s13045_020_00998_9 crossref_primary_10_1136_jitc_2021_002459 crossref_primary_10_3390_cancers15245765 crossref_primary_10_3389_fimmu_2025_1515027 crossref_primary_10_7554_eLife_67106 crossref_primary_10_1182_bloodadvances_2021005045 crossref_primary_10_1186_s13027_023_00495_x crossref_primary_10_18632_aging_205855 crossref_primary_10_1038_s41551_023_01156_5 crossref_primary_10_3389_fimmu_2021_615930 crossref_primary_10_1038_s41422_023_00890_4 crossref_primary_10_1016_j_biomaterials_2024_122731 crossref_primary_10_2147_JIR_S398775 crossref_primary_10_1186_s12943_023_01898_5 crossref_primary_10_1136_jitc_2022_005413 crossref_primary_10_1016_j_canlet_2024_216924 crossref_primary_10_1038_s41598_023_41649_6 crossref_primary_10_3390_antibiotics11111521 crossref_primary_10_1186_s12929_022_00866_3 crossref_primary_10_1007_s12672_024_01575_z crossref_primary_10_1186_s12935_021_02108_2 crossref_primary_10_1002_ange_202407381 crossref_primary_10_1016_j_ajps_2024_100906 crossref_primary_10_3389_fimmu_2021_593255 crossref_primary_10_1080_2162402X_2022_2077898 crossref_primary_10_1016_j_omto_2021_04_010 crossref_primary_10_3389_fonc_2021_680918 crossref_primary_10_3389_fphar_2023_1131342 crossref_primary_10_3390_ijms252413590 crossref_primary_10_3389_fmolb_2021_792154 crossref_primary_10_1158_2159_8290_CD_23_0798 crossref_primary_10_1016_j_apmt_2022_101397 crossref_primary_10_1038_s41416_023_02175_4 crossref_primary_10_1158_1078_0432_CCR_20_4792 crossref_primary_10_1002_ange_202419376 crossref_primary_10_3389_fimmu_2022_935552 crossref_primary_10_1002_adfm_202211698 crossref_primary_10_1002_wnan_1791 crossref_primary_10_1016_j_ctrv_2021_102257 crossref_primary_10_3390_pharmaceutics16040455 crossref_primary_10_1016_j_esmoop_2021_100346 crossref_primary_10_1186_s13293_024_00598_z crossref_primary_10_1016_j_pathol_2022_07_013 crossref_primary_10_1002_adtp_202000243 crossref_primary_10_1126_sciadv_abc2331 crossref_primary_10_12677_ACM_2023_1351081 crossref_primary_10_3389_fonc_2020_610513 crossref_primary_10_1158_2767_9764_CRC_24_0360 crossref_primary_10_1038_s41577_024_01105_6 crossref_primary_10_1016_j_intimp_2020_106876 crossref_primary_10_1002_EXP_20230134 crossref_primary_10_3390_molecules28155804 crossref_primary_10_1016_j_bioactmat_2021_03_008 crossref_primary_10_1038_s41576_022_00553_x crossref_primary_10_3390_pharmaceutics16030411 crossref_primary_10_3389_fimmu_2023_1246682 crossref_primary_10_1038_s41598_024_70897_3 crossref_primary_10_1146_annurev_immunol_070621_030155 crossref_primary_10_3389_fonc_2022_841262 crossref_primary_10_1007_s12672_024_01573_1 crossref_primary_10_1016_j_ajps_2023_100870 crossref_primary_10_3389_fimmu_2022_973601 crossref_primary_10_3389_fonc_2022_961637 crossref_primary_10_1038_s41698_023_00373_0 crossref_primary_10_1080_08820139_2023_2284369 crossref_primary_10_1186_s12951_022_01698_x crossref_primary_10_3389_fonc_2022_961634 crossref_primary_10_3390_curroncol29050238 crossref_primary_10_1016_j_ccell_2020_07_004 crossref_primary_10_3390_ijms231911971 crossref_primary_10_3390_cancers13071569 crossref_primary_10_1002_adma_202206200 crossref_primary_10_1155_2021_3062606 crossref_primary_10_1186_s10020_023_00665_y crossref_primary_10_1016_j_cclet_2023_108346 crossref_primary_10_3389_fphar_2021_687399 crossref_primary_10_1002_advs_202304068 crossref_primary_10_1016_j_apsb_2021_07_025 crossref_primary_10_1016_j_heliyon_2024_e28332 crossref_primary_10_1002_chem_202403508 crossref_primary_10_1158_0008_5472_CAN_21_0468 crossref_primary_10_3389_fimmu_2022_1014861 crossref_primary_10_1016_j_addr_2020_10_004 crossref_primary_10_1021_acscentsci_1c00064 crossref_primary_10_1016_j_addr_2020_10_002 crossref_primary_10_1016_j_heliyon_2023_e18215 crossref_primary_10_1158_1078_0432_CCR_20_2345 crossref_primary_10_1208_s12249_024_02883_x crossref_primary_10_1186_s12014_024_09463_y crossref_primary_10_1038_s41416_023_02318_7 crossref_primary_10_1038_s41587_022_01398_9 crossref_primary_10_1097_CM9_0000000000002217 crossref_primary_10_1126_sciadv_abc3646 crossref_primary_10_1186_s13000_023_01338_4 crossref_primary_10_1007_s00262_022_03336_9 crossref_primary_10_1016_j_annonc_2022_08_084 crossref_primary_10_1097_JS9_0000000000002021 crossref_primary_10_3389_fimmu_2024_1373497 crossref_primary_10_1007_s00262_021_02856_0 crossref_primary_10_2174_1568009623666230414140609 crossref_primary_10_3389_fonc_2021_637023 crossref_primary_10_1002_advs_202308892 crossref_primary_10_1016_j_cell_2024_09_032 crossref_primary_10_3389_fonc_2021_638591 crossref_primary_10_3390_ijms241310625 crossref_primary_10_1002_anbr_202100021 crossref_primary_10_1016_j_biopha_2022_114183 crossref_primary_10_1158_0008_5472_CAN_23_2042 crossref_primary_10_1007_s00432_023_05252_6 crossref_primary_10_1111_jcmm_70297 crossref_primary_10_1038_s41467_023_41016_z crossref_primary_10_3389_fonc_2022_877434 crossref_primary_10_1016_j_actbio_2022_12_039 crossref_primary_10_2217_fon_2022_0615 crossref_primary_10_1016_j_nantod_2022_101621 crossref_primary_10_3389_fphar_2021_677120 crossref_primary_10_3390_cancers15123256 crossref_primary_10_1021_acsbiomaterials_1c01216 crossref_primary_10_1254_fpj_23091 crossref_primary_10_1186_s12951_022_01489_4 crossref_primary_10_1016_j_medidd_2021_100093 crossref_primary_10_1186_s41021_023_00291_4 crossref_primary_10_1073_pnas_2407096121 crossref_primary_10_1126_sciimmunol_ade4656 crossref_primary_10_1002_adma_202007293 crossref_primary_10_1016_j_imbio_2024_152836 crossref_primary_10_2139_ssrn_4131647 crossref_primary_10_1038_s41575_022_00728_1 crossref_primary_10_1002_anie_202407381 crossref_primary_10_3233_MGC_210078 crossref_primary_10_3390_biomedicines12071527 crossref_primary_10_3390_immuno1030010 crossref_primary_10_3389_fimmu_2020_598877 crossref_primary_10_1016_j_eclinm_2023_102156 crossref_primary_10_1186_s13148_025_01856_6 crossref_primary_10_3389_fimmu_2023_1250975 crossref_primary_10_1039_D3NR06333J crossref_primary_10_2147_IJN_S483626 crossref_primary_10_1186_s13244_023_01438_1 crossref_primary_10_1051_medsci_2022093 crossref_primary_10_1186_s12935_023_03194_0 crossref_primary_10_4251_wjgo_v16_i3_919 crossref_primary_10_3389_fgene_2022_981145 crossref_primary_10_1016_j_celrep_2023_113138 crossref_primary_10_1021_acsami_1c11017 crossref_primary_10_1111_eci_13973 crossref_primary_10_1248_bpbreports_3_5_157 crossref_primary_10_1016_j_isci_2023_106330 crossref_primary_10_1038_s41392_024_01979_x crossref_primary_10_1016_j_heliyon_2024_e37054 crossref_primary_10_1080_2162402X_2025_2473163 crossref_primary_10_3389_fonc_2024_1336546 crossref_primary_10_3389_fcell_2023_1209243 crossref_primary_10_1016_j_tranon_2024_101954 crossref_primary_10_1016_j_prp_2022_154241 crossref_primary_10_1016_j_cclet_2023_108536 crossref_primary_10_1136_jitc_2023_008185 crossref_primary_10_3389_fimmu_2021_765898 crossref_primary_10_1002_mnfr_202400750 crossref_primary_10_3389_fimmu_2024_1374390 crossref_primary_10_1016_j_ccell_2024_10_016 crossref_primary_10_1080_2162402X_2021_2006529 crossref_primary_10_1016_j_mtbio_2024_101018 crossref_primary_10_1007_s12672_024_01736_0 crossref_primary_10_1007_s12033_024_01144_3 crossref_primary_10_1186_s12943_024_01986_0 crossref_primary_10_3389_fonc_2023_1126752 crossref_primary_10_1002_adtp_202300340 crossref_primary_10_1016_j_intimp_2023_110975 crossref_primary_10_1016_j_tranon_2022_101366 crossref_primary_10_1021_acs_analchem_3c00409 crossref_primary_10_1007_s00894_023_05690_6 crossref_primary_10_1172_JCI176390 crossref_primary_10_3390_cancers13102365 crossref_primary_10_3389_fonc_2021_726701 crossref_primary_10_3390_ijms24119392 crossref_primary_10_1002_wnan_1776 crossref_primary_10_1186_s12943_024_02197_3 crossref_primary_10_1038_s41571_022_00718_x crossref_primary_10_1016_j_ejca_2020_11_014 crossref_primary_10_1080_2162402X_2023_2210959 crossref_primary_10_3389_fphar_2023_1324212 crossref_primary_10_1002_anie_202419376 crossref_primary_10_18632_aging_204244 crossref_primary_10_1002_agt2_730 crossref_primary_10_1016_j_intimp_2023_111431 crossref_primary_10_1016_j_yexcr_2023_113486 crossref_primary_10_1186_s12943_023_01807_w crossref_primary_10_3389_fonc_2022_812560 crossref_primary_10_3390_cells10102700 crossref_primary_10_3389_fonc_2020_589434 crossref_primary_10_1038_s41467_023_40270_5 crossref_primary_10_3390_cancers12051121 crossref_primary_10_1002_path_5681 crossref_primary_10_1002_smtd_202201457 crossref_primary_10_3389_fmicb_2021_707290 crossref_primary_10_3390_cells12060841 crossref_primary_10_1093_intbio_zyae014 crossref_primary_10_1111_cas_15059 crossref_primary_10_3390_biomedicines10102511 crossref_primary_10_37349_etat_2024_00220 crossref_primary_10_1007_s00018_020_03581_0 crossref_primary_10_1136_gutjnl_2022_328364 crossref_primary_10_1186_s12885_025_13484_7 crossref_primary_10_1136_jitc_2022_005248 crossref_primary_10_1007_s12032_024_02489_0 crossref_primary_10_1016_j_prp_2024_155764 crossref_primary_10_3389_fcell_2021_748442 crossref_primary_10_1016_j_jconrel_2024_11_076 crossref_primary_10_1155_2022_8965903 crossref_primary_10_3389_fimmu_2023_1214675 crossref_primary_10_1016_j_actbio_2023_04_001 crossref_primary_10_1016_j_jconrel_2024_10_035 crossref_primary_10_1158_0008_5472_CAN_24_0220 crossref_primary_10_3390_cancers13040691 crossref_primary_10_1007_s00262_021_02949_w crossref_primary_10_1021_acs_nanolett_4c01711 crossref_primary_10_1002_2211_5463_13698 crossref_primary_10_1080_2162402X_2020_1807291 crossref_primary_10_1002_btm2_10482 crossref_primary_10_1002_advs_202003542 crossref_primary_10_1007_s00262_022_03212_6 crossref_primary_10_1007_s12032_025_02605_8 crossref_primary_10_1016_j_ymthe_2022_09_019 crossref_primary_10_3389_fimmu_2021_682492 crossref_primary_10_1111_cas_16136 crossref_primary_10_3390_molecules28041636 crossref_primary_10_1016_j_ymthe_2022_09_012 crossref_primary_10_3389_fgene_2022_982030 crossref_primary_10_1016_j_envres_2023_115939 crossref_primary_10_1080_2162402X_2020_1784529 crossref_primary_10_1007_s12094_023_03228_z crossref_primary_10_3389_fimmu_2022_994594 crossref_primary_10_1371_journal_pone_0264631 crossref_primary_10_1080_14737159_2023_2281482 crossref_primary_10_3389_fimmu_2023_1126969 crossref_primary_10_1002_med_22023 crossref_primary_10_54751_revistafoco_v17n8_063 crossref_primary_10_3390_ijms24032606 crossref_primary_10_1002_adma_202310078 crossref_primary_10_1007_s10637_023_01335_w crossref_primary_10_3389_fmats_2024_1409310 crossref_primary_10_1155_2022_1749111 crossref_primary_10_1002_smll_202306303 crossref_primary_10_1002_anie_202008083 crossref_primary_10_3390_vaccines9121396 crossref_primary_10_1002_jcla_24437 crossref_primary_10_1038_s41401_022_00953_z crossref_primary_10_3389_fimmu_2021_697964 crossref_primary_10_1002_adma_202107674 crossref_primary_10_1158_1078_0432_CCR_23_1530 crossref_primary_10_2967_jnumed_124_268068 crossref_primary_10_1002_adma_202303542 crossref_primary_10_1186_s41065_023_00293_w crossref_primary_10_3389_fimmu_2024_1472772 crossref_primary_10_1016_j_drup_2022_100907 crossref_primary_10_1016_j_jconrel_2024_10_010 crossref_primary_10_4155_fmc_2021_0301 crossref_primary_10_1002_pro_4867 crossref_primary_10_3390_cells9030587 crossref_primary_10_1016_j_jtho_2023_02_017 crossref_primary_10_3390_cancers16132392 crossref_primary_10_1016_j_cancergen_2025_03_004 crossref_primary_10_1186_s40364_020_00212_5 crossref_primary_10_3389_fimmu_2023_1167018 crossref_primary_10_1016_j_ejca_2021_03_013 crossref_primary_10_3389_fcell_2021_812422 crossref_primary_10_1016_j_actbio_2021_03_076 crossref_primary_10_1002_adbi_202300118 crossref_primary_10_3390_cancers14215317 crossref_primary_10_1038_s41419_024_07073_y crossref_primary_10_3389_fchem_2023_1283924 crossref_primary_10_1088_1758_5090_ad847f crossref_primary_10_3390_cells11010179 crossref_primary_10_3390_ijms24043762 crossref_primary_10_1038_s41467_023_40886_7 crossref_primary_10_1002_adma_202209379 crossref_primary_10_1016_j_ijpharm_2023_123459 crossref_primary_10_1007_s00262_024_03737_y crossref_primary_10_1016_j_esmoop_2024_103665 crossref_primary_10_1038_s41467_024_53911_0 crossref_primary_10_3389_fonc_2020_01098 crossref_primary_10_1001_jamanetworkopen_2022_4637 crossref_primary_10_1007_s12094_024_03798_6 crossref_primary_10_1136_jitc_2022_006533 crossref_primary_10_3389_fonc_2023_1234045 crossref_primary_10_1016_j_bbrep_2025_101950 crossref_primary_10_1016_j_nut_2022_111829 crossref_primary_10_3390_pharmaceutics14081630 crossref_primary_10_1016_j_ejca_2021_04_035 crossref_primary_10_1038_s41379_020_00664_y crossref_primary_10_1007_s10928_021_09790_9 crossref_primary_10_1016_j_isci_2024_109062 crossref_primary_10_1186_s12935_023_03056_9 crossref_primary_10_1016_j_oraloncology_2022_105755 crossref_primary_10_1016_j_isci_2022_105382 crossref_primary_10_1158_2326_6066_CIR_23_0718 crossref_primary_10_1186_s12943_021_01479_4 crossref_primary_10_3389_fimmu_2022_875093 crossref_primary_10_1016_j_mtbio_2023_100926 crossref_primary_10_1186_s12951_025_03236_x crossref_primary_10_1038_s41598_024_72985_w crossref_primary_10_1080_21645515_2023_2269794 crossref_primary_10_1039_D3TB02787B crossref_primary_10_3389_fonc_2023_1282335 crossref_primary_10_1080_17460441_2023_2216016 crossref_primary_10_1016_j_intimp_2024_112820 crossref_primary_10_1002_btm2_10417 crossref_primary_10_1186_s12951_023_01786_6 crossref_primary_10_1021_acsami_4c05172 crossref_primary_10_1002_btm2_10651 crossref_primary_10_3389_fonc_2024_1483454 crossref_primary_10_1039_D4TB01995D crossref_primary_10_3390_cancers15072009 crossref_primary_10_1016_j_lungcan_2023_107257 crossref_primary_10_1039_D3TB01677C crossref_primary_10_1039_D3BM00248A crossref_primary_10_1182_blood_2021014495 crossref_primary_10_3390_ijms24043777 crossref_primary_10_1038_s42003_021_02565_5 crossref_primary_10_1038_s41392_024_01826_z crossref_primary_10_1080_01932691_2025_2476111 crossref_primary_10_18632_aging_204076 crossref_primary_10_3389_fphar_2022_956788 crossref_primary_10_1186_s12935_024_03295_4 crossref_primary_10_1016_j_bcp_2025_116803 crossref_primary_10_1002_smsc_202100117 crossref_primary_10_3389_fimmu_2022_976739 crossref_primary_10_1098_rsos_211991 crossref_primary_10_1111_cyt_13226 crossref_primary_10_14348_molcells_2021_0130 crossref_primary_10_1186_s12885_023_11672_x crossref_primary_10_1038_s41588_023_01570_0 crossref_primary_10_1016_j_oraloncology_2021_105472 crossref_primary_10_12688_f1000research_134244_1 crossref_primary_10_12688_f1000research_134244_2 crossref_primary_10_2217_imt_2022_0168 crossref_primary_10_3389_fimmu_2023_1237361 crossref_primary_10_1016_j_it_2023_10_002 crossref_primary_10_1007_s12195_023_00770_2 crossref_primary_10_1155_2022_2528164 crossref_primary_10_3390_cancers13030440 crossref_primary_10_1016_j_biomaterials_2024_123028 crossref_primary_10_1016_j_onano_2023_100134 crossref_primary_10_1038_s41598_023_50787_w crossref_primary_10_1186_s12951_021_00805_8 crossref_primary_10_1016_j_isci_2023_108055 crossref_primary_10_1002_adma_202211130 crossref_primary_10_3390_genes13112080 crossref_primary_10_1007_s12094_024_03818_5 crossref_primary_10_1016_j_gendis_2025_101599 crossref_primary_10_1136_jitc_2021_002787 crossref_primary_10_3389_fimmu_2023_1081790 crossref_primary_10_1016_j_ejphar_2023_176013 crossref_primary_10_3390_ijms23042022 crossref_primary_10_1016_j_critrevonc_2020_103068 crossref_primary_10_1016_j_copbio_2020_08_012 crossref_primary_10_1155_2022_9133636 crossref_primary_10_3390_cancers13133356 crossref_primary_10_1186_s12967_024_05923_z crossref_primary_10_3389_fimmu_2023_1183578 crossref_primary_10_3389_fchem_2021_629635 crossref_primary_10_3390_cancers13030473 crossref_primary_10_1007_s12328_022_01697_3 crossref_primary_10_1016_j_drup_2025_101206 crossref_primary_10_3389_fonc_2022_916251 crossref_primary_10_1016_j_bbcan_2025_189267 crossref_primary_10_3389_fphar_2022_990445 crossref_primary_10_3389_fimmu_2021_701485 crossref_primary_10_3390_biomedicines9060640 crossref_primary_10_3389_fgene_2022_893380 crossref_primary_10_1016_j_biopha_2022_113464 crossref_primary_10_1016_j_heliyon_2024_e24988 crossref_primary_10_3389_fimmu_2021_701006 crossref_primary_10_3389_fimmu_2022_845193 crossref_primary_10_1016_j_intimp_2024_111781 crossref_primary_10_1080_2162402X_2021_1944553 crossref_primary_10_1038_s41467_023_38014_6 crossref_primary_10_3389_fimmu_2024_1367040 crossref_primary_10_1093_jnci_djad151 crossref_primary_10_3389_fbioe_2022_989881 crossref_primary_10_3390_cells12172147 crossref_primary_10_1016_j_semcancer_2022_05_006 crossref_primary_10_1186_s40164_024_00511_9 crossref_primary_10_3390_life11121318 crossref_primary_10_1016_j_annonc_2022_02_004 crossref_primary_10_1038_s41423_020_0488_6 crossref_primary_10_1016_j_heliyon_2022_e12191 crossref_primary_10_1016_j_bios_2022_114166 crossref_primary_10_1016_j_chembiol_2023_09_001 crossref_primary_10_1038_s41576_025_00821_6 crossref_primary_10_1038_s42003_021_02972_8 crossref_primary_10_1016_j_bcp_2020_114258 crossref_primary_10_1515_nanoph_2021_0196 crossref_primary_10_3390_cancers13236016 crossref_primary_10_1007_s00277_024_06117_9 crossref_primary_10_1002_mc_23192 crossref_primary_10_1016_j_cej_2025_159533 crossref_primary_10_1042_BSR20221546 crossref_primary_10_1016_j_ijbiomac_2023_124929 crossref_primary_10_1186_s13046_021_01872_3 crossref_primary_10_1002_advs_201903394 crossref_primary_10_3389_fmolb_2022_937979 crossref_primary_10_1186_s12943_024_02014_x crossref_primary_10_2139_ssrn_3738656 crossref_primary_10_1016_j_ejmech_2021_113967 crossref_primary_10_3389_fgene_2021_763636 crossref_primary_10_1002_1878_0261_12654 crossref_primary_10_1111_odi_14367 crossref_primary_10_1016_j_cyto_2023_156249 crossref_primary_10_1038_s41525_021_00249_x crossref_primary_10_1007_s10142_023_01281_z crossref_primary_10_3390_biomedicines11123140 crossref_primary_10_1016_j_addr_2020_07_023 crossref_primary_10_1039_D3LC00662J crossref_primary_10_1111_cas_16309 crossref_primary_10_59717_j_xinn_med_2024_100052 crossref_primary_10_3390_ph16101384 crossref_primary_10_1002_adfm_202207749 crossref_primary_10_4251_wjgo_v15_i1_55 crossref_primary_10_3390_pharmaceutics13091338 crossref_primary_10_3389_fimmu_2024_1486652 crossref_primary_10_3389_fphar_2022_885699 crossref_primary_10_1002_ange_202210988 crossref_primary_10_1158_1078_0432_CCR_21_0136 crossref_primary_10_1016_j_intimp_2024_112609 crossref_primary_10_1016_j_tranon_2024_102181 crossref_primary_10_1001_jamanetworkopen_2024_23390 crossref_primary_10_1186_s40364_023_00460_1 crossref_primary_10_3389_fgene_2022_1067524 crossref_primary_10_3389_fonc_2021_711020 crossref_primary_10_1038_s41423_024_01232_z crossref_primary_10_1080_14712598_2023_2201371 crossref_primary_10_3390_pharmaceutics14081589 crossref_primary_10_1038_s41598_023_48653_w crossref_primary_10_1158_1078_0432_CCR_21_1252 crossref_primary_10_1007_s12672_024_01534_8 crossref_primary_10_1186_s13045_021_01075_5 crossref_primary_10_1016_j_oraloncology_2021_105640 crossref_primary_10_1002_JLB_5MR0321_170R crossref_primary_10_1007_s11686_023_00680_3 crossref_primary_10_1002_smll_202300544 crossref_primary_10_15251_DJNB_2024_194_1903 crossref_primary_10_3390_ijms24010041 crossref_primary_10_1002_eji_202451440 crossref_primary_10_1021_acsabm_2c00963 crossref_primary_10_1038_s41598_022_13764_3 crossref_primary_10_1016_j_eng_2023_05_004 crossref_primary_10_1016_j_semcancer_2022_12_003 crossref_primary_10_1186_s13073_022_01146_3 crossref_primary_10_1016_j_canlet_2022_215918 crossref_primary_10_1038_s41698_022_00305_4 crossref_primary_10_1002_adhm_202203028 crossref_primary_10_3390_cancers13133313 crossref_primary_10_1172_jci_insight_168517 crossref_primary_10_1002_smtd_202300347 crossref_primary_10_3389_fimmu_2021_625667 crossref_primary_10_1016_j_lfs_2020_118110 crossref_primary_10_1360_TB_2024_0081 crossref_primary_10_1126_sciadv_ade4186 crossref_primary_10_1038_s41586_023_06069_6 crossref_primary_10_3390_cells9061525 crossref_primary_10_3389_fonc_2021_819817 crossref_primary_10_3389_fbioe_2023_1220074 crossref_primary_10_1016_j_phrs_2023_106988 crossref_primary_10_1136_jitc_2022_006374 crossref_primary_10_1016_j_jtho_2021_07_015 crossref_primary_10_1002_hep_32444 crossref_primary_10_1038_s41418_024_01432_0 crossref_primary_10_1016_j_jconrel_2025_113620 crossref_primary_10_3390_pharmaceutics14081566 crossref_primary_10_1007_s11431_023_2574_0 crossref_primary_10_3390_pharmaceutics14081564 crossref_primary_10_1158_1535_7163_MCT_22_0475 crossref_primary_10_1016_j_cej_2023_143827 crossref_primary_10_1002_adma_202106390 crossref_primary_10_1186_s13046_020_01820_7 crossref_primary_10_1016_j_biomaterials_2023_122392 crossref_primary_10_1016_j_slast_2024_100232 crossref_primary_10_1038_s41586_023_05704_6 crossref_primary_10_1111_1759_7714_14929 crossref_primary_10_1038_s41598_024_65957_7 crossref_primary_10_1186_s12951_022_01736_8 crossref_primary_10_1016_j_bbcan_2024_189161 crossref_primary_10_1155_2021_9920421 crossref_primary_10_3389_fimmu_2021_807895 crossref_primary_10_3389_fimmu_2023_1055671 crossref_primary_10_3389_fimmu_2024_1285049 crossref_primary_10_1371_journal_pone_0303875 crossref_primary_10_1016_j_ccell_2023_02_016 crossref_primary_10_3389_fonc_2022_847350 crossref_primary_10_1016_j_ejca_2022_04_039 crossref_primary_10_31083_j_fbl2902052 crossref_primary_10_1158_2767_9764_CRC_22_0278 crossref_primary_10_1016_j_apsb_2024_02_015 crossref_primary_10_3389_fcell_2022_818744 crossref_primary_10_34133_bmr_0008 crossref_primary_10_1007_s00262_024_03881_5 crossref_primary_10_1016_j_trecan_2022_01_008 crossref_primary_10_1016_j_canlet_2021_06_005 crossref_primary_10_1016_j_omto_2021_07_011 crossref_primary_10_12677_ACM_2024_142647 crossref_primary_10_1126_sciadv_adg2809 crossref_primary_10_1186_s12935_022_02834_1 crossref_primary_10_1371_journal_pone_0265264 crossref_primary_10_1158_1541_7786_MCR_24_0880 crossref_primary_10_1038_s41571_021_00565_2 crossref_primary_10_1007_s00262_024_03908_x crossref_primary_10_1158_2326_6066_CIR_22_0926 crossref_primary_10_3389_fonc_2022_1104877 crossref_primary_10_3390_vaccines10050740 crossref_primary_10_3389_fmolb_2021_672531 crossref_primary_10_1007_s00432_025_06095_z crossref_primary_10_3390_therapeutics1020011 crossref_primary_10_1186_s40478_023_01569_y crossref_primary_10_31083_j_fbl2804069 crossref_primary_10_7554_eLife_87586 crossref_primary_10_3390_cancers13184540 crossref_primary_10_3892_or_2024_8757 crossref_primary_10_26599_NTM_2022_9130001 crossref_primary_10_1155_2022_2249909 crossref_primary_10_1186_s12943_023_01844_5 crossref_primary_10_1016_j_ctrv_2025_102881 crossref_primary_10_1007_s00262_024_03689_3 crossref_primary_10_3389_fphar_2023_1195864 crossref_primary_10_1038_s41416_022_01703_y crossref_primary_10_1038_s41388_022_02201_4 crossref_primary_10_3390_jcm13216537 crossref_primary_10_1038_s41467_021_27331_3 crossref_primary_10_3390_pharmaceutics14122606 crossref_primary_10_3389_fimmu_2023_1142862 crossref_primary_10_7717_peerj_18457 crossref_primary_10_1007_s11033_024_09418_4 crossref_primary_10_1186_s12951_022_01682_5 crossref_primary_10_1016_j_immuni_2024_03_020 crossref_primary_10_1007_s11864_022_00994_w crossref_primary_10_3350_cmh_2024_0296 crossref_primary_10_1080_21645515_2021_1889449 crossref_primary_10_1007_s40820_023_01125_2 crossref_primary_10_1016_j_colsurfb_2022_112389 crossref_primary_10_1016_j_ajps_2022_07_005 crossref_primary_10_1002_cac2_12487 crossref_primary_10_1002_adbi_202200263 crossref_primary_10_3390_cancers12092497 crossref_primary_10_1097_MD_0000000000036315 crossref_primary_10_2967_jnumed_120_246041 crossref_primary_10_1136_jitc_2023_008269 crossref_primary_10_1186_s40364_023_00540_2 crossref_primary_10_1016_j_canlet_2024_216741 crossref_primary_10_1080_21645515_2020_1782692 crossref_primary_10_3390_vaccines10010078 crossref_primary_10_1093_nsr_nwae020 crossref_primary_10_1038_s41467_022_29366_6 crossref_primary_10_1080_14712598_2022_2027904 crossref_primary_10_3389_fimmu_2021_651086 crossref_primary_10_1080_2162402X_2020_1817653 crossref_primary_10_1186_s12876_023_02843_y crossref_primary_10_3390_cancers14122938 crossref_primary_10_31083_j_fbl2903104 crossref_primary_10_1007_s12185_022_03436_3 crossref_primary_10_1016_j_jconrel_2024_09_041 crossref_primary_10_1016_j_semcancer_2022_03_007 crossref_primary_10_1186_s13046_024_03250_1 crossref_primary_10_19163_2307_9266_2023_11_5_384_398 crossref_primary_10_1186_s13045_021_01125_y crossref_primary_10_3390_biology12121528 crossref_primary_10_3389_fphar_2022_954955 crossref_primary_10_1002_bmm2_12112 crossref_primary_10_1016_j_ijpharm_2024_125068 crossref_primary_10_1038_s41568_021_00347_z crossref_primary_10_1016_j_ebiom_2024_105177 crossref_primary_10_3389_fimmu_2023_1288027 crossref_primary_10_1016_j_ymthe_2022_05_011 crossref_primary_10_1007_s00795_025_00419_1 crossref_primary_10_1016_j_intimp_2021_108374 crossref_primary_10_1002_smll_202104849 crossref_primary_10_1002_ctm2_1416 crossref_primary_10_1016_j_celrep_2024_113712 crossref_primary_10_1136_bcr_2021_247676 crossref_primary_10_1152_ajpcell_00151_2022 crossref_primary_10_1177_17588359241253127 crossref_primary_10_1016_j_ccell_2023_03_009 crossref_primary_10_1021_acsbiomaterials_1c00081 crossref_primary_10_3390_cancers16213711 crossref_primary_10_3389_fgene_2022_903634 crossref_primary_10_3389_fmolb_2022_807497 crossref_primary_10_2147_DDDT_S374672 crossref_primary_10_2147_IJN_S455213 crossref_primary_10_1186_s12885_023_11647_y crossref_primary_10_3390_ijms22052608 crossref_primary_10_3389_frlct_2024_1487377 crossref_primary_10_1038_s43018_021_00263_z crossref_primary_10_1136_jitc_2024_009893 crossref_primary_10_12968_hmed_2024_0375 crossref_primary_10_1007_s42764_024_00131_x crossref_primary_10_1002_advs_202301216 crossref_primary_10_2217_mmt_2023_0006 crossref_primary_10_3389_fonc_2020_00446 crossref_primary_10_1371_journal_pone_0264384 crossref_primary_10_1016_j_ijbiomac_2023_123161 crossref_primary_10_1016_j_coi_2024_102422 crossref_primary_10_3389_fphar_2024_1417576 crossref_primary_10_1186_s13036_021_00264_7 crossref_primary_10_3389_fimmu_2024_1399926 crossref_primary_10_1021_acs_jmedchem_4c00568 crossref_primary_10_1158_1078_0432_CCR_22_2757 crossref_primary_10_3390_cells13040346 crossref_primary_10_1080_26895293_2022_2163306 crossref_primary_10_3389_fimmu_2024_1444424 crossref_primary_10_1146_annurev_cancerbio_070120_094725 crossref_primary_10_2147_JIR_S383191 crossref_primary_10_3389_fimmu_2022_978377 crossref_primary_10_1152_ajpcell_00063_2022 crossref_primary_10_1016_j_canlet_2021_05_032 crossref_primary_10_3389_fgene_2020_598118 crossref_primary_10_4049_jimmunol_2300220 crossref_primary_10_1186_s12885_023_10605_y crossref_primary_10_1158_2767_9764_CRC_23_0432 crossref_primary_10_1038_s42003_024_06087_8 crossref_primary_10_1002_anie_202308413 crossref_primary_10_3390_cancers12071757 crossref_primary_10_1016_j_biopha_2024_117553 crossref_primary_10_1172_JCI162951 crossref_primary_10_1136_jitc_2020_002045 crossref_primary_10_3390_cancers15184433 crossref_primary_10_1007_s13346_022_01258_8 crossref_primary_10_1186_s12909_022_03847_0 crossref_primary_10_1186_s12967_025_06178_y crossref_primary_10_1016_j_cej_2023_146938 crossref_primary_10_1007_s00432_024_05606_8 crossref_primary_10_1007_s11307_021_01688_9 crossref_primary_10_1016_j_ejca_2021_08_003 crossref_primary_10_1155_2022_6906380 crossref_primary_10_3389_fimmu_2022_947885 crossref_primary_10_1038_s41598_023_39365_2 crossref_primary_10_47162_RJME_65_2_01 crossref_primary_10_1371_journal_pone_0296193 crossref_primary_10_3390_cancers15010272 crossref_primary_10_3390_vaccines10081272 crossref_primary_10_3389_fcell_2021_707073 crossref_primary_10_1038_s41467_023_40398_4 crossref_primary_10_1016_j_esmoop_2025_104498 crossref_primary_10_1002_bies_202000024 crossref_primary_10_1021_acsnano_4c11757 crossref_primary_10_1146_annurev_bioeng_110320_110749 crossref_primary_10_1021_accountsmr_2c00042 crossref_primary_10_1158_1535_7163_MCT_24_0125 crossref_primary_10_1007_s11547_023_01710_w crossref_primary_10_3390_cancers13235999 crossref_primary_10_3389_fimmu_2022_941092 crossref_primary_10_3389_fimmu_2022_987298 crossref_primary_10_3389_fimmu_2024_1442027 crossref_primary_10_1002_mef2_56 crossref_primary_10_56294_piii2024333 crossref_primary_10_1016_j_ijbiomac_2021_05_073 crossref_primary_10_1111_cas_14572 crossref_primary_10_1016_j_nantod_2022_101555 crossref_primary_10_1016_j_compbiomed_2023_106622 crossref_primary_10_1038_s43018_022_00447_1 crossref_primary_10_3389_fimmu_2022_961926 crossref_primary_10_1038_s41401_022_01020_3 crossref_primary_10_1002_cam4_4845 crossref_primary_10_1182_bloodadvances_2020003955 crossref_primary_10_1007_s11655_023_3749_2 crossref_primary_10_1089_gtmb_2023_0108 crossref_primary_10_1002_wnan_1665 crossref_primary_10_1038_s41420_024_01799_6 crossref_primary_10_1007_s00262_022_03326_x crossref_primary_10_1016_j_bmc_2023_117382 crossref_primary_10_3389_fimmu_2022_909027 crossref_primary_10_2139_ssrn_3738078 crossref_primary_10_1016_j_ijbiomac_2022_11_277 crossref_primary_10_1038_s41467_022_32567_8 crossref_primary_10_1186_s12943_025_02225_w crossref_primary_10_1002_smll_202405470 crossref_primary_10_3390_cancers12051082 crossref_primary_10_2217_fon_2023_0658 crossref_primary_10_1166_jbn_2024_3741 crossref_primary_10_1021_acs_nanolett_2c03899 crossref_primary_10_3389_fimmu_2022_845757 crossref_primary_10_1007_s10549_022_06818_7 crossref_primary_10_1186_s12964_021_00769_0 crossref_primary_10_2217_imt_2021_0097 crossref_primary_10_1007_s11523_021_00809_2 crossref_primary_10_1016_j_molmed_2021_06_014 crossref_primary_10_2139_ssrn_4016604 crossref_primary_10_1016_j_biopha_2022_112923 crossref_primary_10_1136_jitc_2022_005769 crossref_primary_10_1038_s41392_023_01674_3 crossref_primary_10_1111_cts_13312 crossref_primary_10_1002_cac2_12313 crossref_primary_10_1021_acs_nanolett_4c01678 crossref_primary_10_3389_fimmu_2022_1080048 crossref_primary_10_3389_fbioe_2024_1484577 crossref_primary_10_1002_adbi_201900311 crossref_primary_10_2482_haigan_62_81 crossref_primary_10_1002_advs_202409381 crossref_primary_10_3389_fonc_2021_697219 crossref_primary_10_1002_adma_202413210 crossref_primary_10_1080_2162402X_2021_1969075 crossref_primary_10_1038_s41420_021_00769_6 crossref_primary_10_1088_1748_605X_ad971e crossref_primary_10_3389_fimmu_2022_894707 crossref_primary_10_3389_fimmu_2024_1342647 crossref_primary_10_1016_j_addr_2020_09_001 crossref_primary_10_1016_j_bbrc_2023_02_083 crossref_primary_10_2174_0115733947263244231002042219 crossref_primary_10_7554_eLife_82998 crossref_primary_10_1016_j_apsb_2024_05_013 crossref_primary_10_3389_fimmu_2024_1420463 crossref_primary_10_3389_fonc_2022_1018333 crossref_primary_10_1186_s40164_024_00506_6 crossref_primary_10_3233_MGC_210185 crossref_primary_10_3390_biom14020171 crossref_primary_10_1159_000533952 crossref_primary_10_1007_s12672_025_01810_1 crossref_primary_10_1016_j_ccell_2021_09_010 crossref_primary_10_1038_s41590_021_00982_6 crossref_primary_10_1093_bfgp_elab040 crossref_primary_10_3389_fimmu_2024_1328145 crossref_primary_10_1002_cam4_5954 crossref_primary_10_1002_1878_0261_13190 crossref_primary_10_1016_j_jics_2022_100803 crossref_primary_10_1016_j_nantod_2021_101209 crossref_primary_10_3389_fimmu_2022_923477 crossref_primary_10_1136_jitc_2023_006923 crossref_primary_10_1631_jzus_B2200195 crossref_primary_10_1016_j_cej_2024_156545 crossref_primary_10_1186_s12967_023_04804_1 crossref_primary_10_3389_fonc_2021_757993 crossref_primary_10_1016_j_cpet_2023_02_006 crossref_primary_10_1007_s12274_023_5786_8 crossref_primary_10_3390_cancers13040701 crossref_primary_10_1016_j_bioactmat_2024_09_008 crossref_primary_10_1097_MD_0000000000035196 crossref_primary_10_3389_fonc_2021_732214 crossref_primary_10_1155_2023_7620181 crossref_primary_10_3390_cancers15215257 crossref_primary_10_1038_s41420_021_00527_8 crossref_primary_10_1158_1078_0432_CCR_20_1135 crossref_primary_10_2967_jnumed_124_268586 crossref_primary_10_1016_j_canlet_2023_216318 crossref_primary_10_3389_fimmu_2022_892512 crossref_primary_10_1002_cac2_12539 crossref_primary_10_3390_cancers13102288 crossref_primary_10_1002_adhm_202301174 crossref_primary_10_1007_s15004_021_8731_6 crossref_primary_10_1158_2767_9764_CRC_24_0270 crossref_primary_10_1186_s13578_020_00481_5 crossref_primary_10_1016_j_nantod_2021_101211 crossref_primary_10_1136_jcp_2022_208601 crossref_primary_10_3390_ijms22158035 crossref_primary_10_2139_ssrn_4073645 crossref_primary_10_1002_advs_202403858 crossref_primary_10_1186_s12951_022_01760_8 crossref_primary_10_1177_17588359231189436 crossref_primary_10_3390_biomedicines11082160 crossref_primary_10_3390_biomedicines8070204 crossref_primary_10_1016_j_nantod_2024_102164 crossref_primary_10_1002_med_21876 crossref_primary_10_1016_j_ccr_2023_215624 crossref_primary_10_3390_cancers14122876 crossref_primary_10_1016_j_ccell_2021_03_007 crossref_primary_10_1021_acs_nanolett_2c01280 crossref_primary_10_3389_fimmu_2024_1457691 crossref_primary_10_1016_j_immuni_2023_09_011 crossref_primary_10_1080_10717544_2022_2161670 crossref_primary_10_1016_j_apsb_2022_02_014 crossref_primary_10_1016_j_biomaterials_2022_121677 crossref_primary_10_3390_cancers15051608 crossref_primary_10_1002_mog2_70012 crossref_primary_10_1038_s41551_025_01357_0 crossref_primary_10_1158_0008_5472_CAN_24_0940 crossref_primary_10_1080_21655979_2021_1955511 crossref_primary_10_1016_j_cej_2022_138139 crossref_primary_10_1016_j_cpt_2023_06_004 crossref_primary_10_1016_j_jconrel_2024_09_044 crossref_primary_10_1038_s41417_020_00248_7 crossref_primary_10_1016_j_mattod_2023_03_025 crossref_primary_10_1111_imm_13573 crossref_primary_10_1002_adma_202401667 crossref_primary_10_3390_molecules30061257 crossref_primary_10_1080_15384047_2025_2455722 crossref_primary_10_18632_aging_205464 crossref_primary_10_1016_j_jncc_2021_11_006 crossref_primary_10_1002_ctm2_1802 crossref_primary_10_1007_s00281_022_00979_9 crossref_primary_10_1007_s00018_022_04431_x crossref_primary_10_1002_cam4_4812 crossref_primary_10_1002_wnan_1873 crossref_primary_10_1186_s13045_025_01678_2 crossref_primary_10_1016_j_jcis_2021_06_174 crossref_primary_10_1038_s41568_025_00798_8 crossref_primary_10_1080_21655979_2021_2011631 crossref_primary_10_1109_JBHI_2023_3334709 crossref_primary_10_1101_cshperspect_a041330 crossref_primary_10_3390_cancers14225647 crossref_primary_10_3390_vaccines9060647 crossref_primary_10_1002_adma_202208553 crossref_primary_10_1002_path_5772 crossref_primary_10_1016_j_patcog_2022_108827 crossref_primary_10_3389_fphar_2022_901563 crossref_primary_10_1016_j_mtbio_2025_101683 crossref_primary_10_1186_s12964_024_01622_w crossref_primary_10_1002_advs_202414769 crossref_primary_10_1007_s00109_024_02488_8 crossref_primary_10_15406_atroa_2024_10_00150 crossref_primary_10_7554_eLife_87586_3 crossref_primary_10_1038_s41416_023_02392_x crossref_primary_10_3389_fonc_2024_1328844 crossref_primary_10_1002_advs_202309203 crossref_primary_10_1016_j_celrep_2024_114868 crossref_primary_10_1021_acsami_3c02646 crossref_primary_10_1186_s12951_024_02413_8 crossref_primary_10_3389_fgene_2024_1285305 crossref_primary_10_2147_OTT_S247836 crossref_primary_10_1016_j_canlet_2024_216824 crossref_primary_10_3390_cells11223606 crossref_primary_10_1136_jitc_2022_005514 crossref_primary_10_1002_cbin_12053 crossref_primary_10_1007_s12672_025_01821_y crossref_primary_10_1016_j_addr_2021_03_015 crossref_primary_10_1016_j_scib_2024_01_025 crossref_primary_10_1016_j_mtbio_2024_101375 crossref_primary_10_1186_s12964_024_01633_7 crossref_primary_10_2139_ssrn_4014215 crossref_primary_10_1007_s00120_020_01198_6 crossref_primary_10_1016_j_biomaterials_2024_122469 crossref_primary_10_1038_s41591_024_03360_5 crossref_primary_10_3390_ijms242015332 crossref_primary_10_1002_adbi_202200293 crossref_primary_10_1016_j_vacun_2023_10_006 crossref_primary_10_1007_s00262_023_03581_6 crossref_primary_10_1016_j_lfs_2024_122652 crossref_primary_10_1007_s12032_023_02023_8 crossref_primary_10_1038_s41568_024_00779_3 crossref_primary_10_1007_s12672_023_00789_x crossref_primary_10_3389_fonc_2022_1008753 crossref_primary_10_1038_s41591_024_03088_2 crossref_primary_10_1080_07357907_2024_2301733 crossref_primary_10_1002_mco2_359 crossref_primary_10_1186_s12943_023_01735_9 crossref_primary_10_1002_mco2_355 crossref_primary_10_3389_fimmu_2022_843106 crossref_primary_10_1158_0008_5472_CAN_22_0094 crossref_primary_10_1002_adma_202004788 crossref_primary_10_3390_cells12020273 crossref_primary_10_1007_s00018_022_04462_4 crossref_primary_10_1042_EBC20220247 crossref_primary_10_3389_fimmu_2022_881453 crossref_primary_10_1136_jitc_2023_006749 crossref_primary_10_1016_j_annonc_2021_08_2153 crossref_primary_10_3389_fcell_2022_896080 crossref_primary_10_1038_s41419_024_06616_7 crossref_primary_10_3389_fonc_2022_861601 crossref_primary_10_1016_j_ccell_2021_04_004 crossref_primary_10_3390_cells10050977 crossref_primary_10_3389_fimmu_2022_1006501 crossref_primary_10_1172_jci_insight_152815 crossref_primary_10_1016_j_cej_2022_137889 crossref_primary_10_1016_j_actbio_2021_09_052 crossref_primary_10_3390_ph16071042 crossref_primary_10_1002_anie_202210988 crossref_primary_10_3390_jcm13237131 crossref_primary_10_2139_ssrn_4053884 crossref_primary_10_3390_biomedicines10061441 crossref_primary_10_1016_j_heliyon_2023_e15494 crossref_primary_10_1186_s12944_024_02429_x crossref_primary_10_1016_j_pathol_2020_09_004 crossref_primary_10_1002_adfm_202104472 crossref_primary_10_1159_000540875 crossref_primary_10_1016_j_devcel_2022_01_002 crossref_primary_10_1136_jitc_2023_007841 crossref_primary_10_1038_s41467_023_40850_5 crossref_primary_10_1186_s12943_024_02192_8 crossref_primary_10_1021_acsnano_3c05882 crossref_primary_10_1016_j_adcanc_2022_100033 crossref_primary_10_3389_fgene_2022_1008644 crossref_primary_10_1021_acs_molpharmaceut_2c00709 crossref_primary_10_1016_j_nantod_2023_102003 crossref_primary_10_1016_j_xcrm_2023_100932 crossref_primary_10_3390_jfb13030146 crossref_primary_10_3892_etm_2022_11554 crossref_primary_10_1002_jbt_22900 crossref_primary_10_3390_cancers13040785 crossref_primary_10_1097_MD_0000000000028057 crossref_primary_10_1158_1078_0432_CCR_23_0315 crossref_primary_10_1002_advs_202001447 crossref_primary_10_1136_jitc_2022_006243 crossref_primary_10_3389_fimmu_2022_859785 crossref_primary_10_3390_cancers14030510 crossref_primary_10_1002_adfm_202409319 crossref_primary_10_1136_jitc_2023_007854 crossref_primary_10_4103_jcrt_JCRT_1241_20 crossref_primary_10_1186_s40001_023_01125_3 crossref_primary_10_3389_fimmu_2024_1428596 crossref_primary_10_1186_s40364_024_00621_w crossref_primary_10_3389_fimmu_2023_1259461 crossref_primary_10_3389_fmolb_2022_777775 crossref_primary_10_1039_D3TB00221G crossref_primary_10_3389_fimmu_2024_1325946 crossref_primary_10_1002_adhm_202203264 crossref_primary_10_1038_s41698_021_00193_0 crossref_primary_10_3390_molecules27041303 crossref_primary_10_1038_s41571_023_00789_4 crossref_primary_10_1002_btm2_10588 crossref_primary_10_3390_jpm14070765 crossref_primary_10_1016_j_cej_2025_159941 crossref_primary_10_1016_j_biopha_2023_114756 crossref_primary_10_1186_s12935_024_03546_4 crossref_primary_10_1186_s13046_022_02474_3 crossref_primary_10_1016_j_amc_2021_126052 crossref_primary_10_1016_j_fmre_2022_11_003 crossref_primary_10_1158_2159_8290_CD_23_0486 crossref_primary_10_3390_ijms22179118 crossref_primary_10_1002_mco2_714 crossref_primary_10_1002_ange_202004206 crossref_primary_10_3389_fcell_2022_1013885 crossref_primary_10_1038_s41419_023_05753_9 crossref_primary_10_3390_cancers13194906 crossref_primary_10_1186_s12967_023_04336_8 crossref_primary_10_1093_jjco_hyae058 crossref_primary_10_3390_ijms232113258 crossref_primary_10_1515_nanoph_2021_0171 crossref_primary_10_1002_JLB_1MR0520_746R crossref_primary_10_1039_D2NH00590E crossref_primary_10_1016_j_vacune_2024_02_012 crossref_primary_10_1021_acsnano_4c12197 crossref_primary_10_1016_j_ijbiomac_2024_137061 crossref_primary_10_1016_j_intimp_2024_112722 crossref_primary_10_37349_emed_2021_00043 crossref_primary_10_1016_j_apsb_2025_02_022 crossref_primary_10_1158_2326_6066_CIR_23_0851 crossref_primary_10_1016_j_canlet_2022_215995 crossref_primary_10_1097_MD_0000000000040361 crossref_primary_10_1158_1541_7786_MCR_21_0147 crossref_primary_10_1007_s00066_021_01752_x crossref_primary_10_1021_acsnano_1c02391 crossref_primary_10_1042_BSR20212051 crossref_primary_10_3389_fneur_2021_704130 crossref_primary_10_4049_immunohorizons_2200062 crossref_primary_10_1002_advs_202306348 crossref_primary_10_1186_s40164_024_00543_1 crossref_primary_10_3390_cancers13051018 crossref_primary_10_2174_0113862073296206240416060154 crossref_primary_10_1126_scitranslmed_abo3605 crossref_primary_10_1080_21645515_2023_2219191 crossref_primary_10_1002_advs_202304160 crossref_primary_10_1038_s41586_022_05254_3 crossref_primary_10_1039_D3NR05457H crossref_primary_10_1063_5_0030693 crossref_primary_10_3389_fimmu_2023_1073681 crossref_primary_10_1002_ange_202308413 crossref_primary_10_1016_j_ygyno_2021_07_001 crossref_primary_10_1002_1878_0261_13582 crossref_primary_10_1136_jitc_2023_007805 crossref_primary_10_1038_s41598_023_32238_8 crossref_primary_10_3390_ph14090884 crossref_primary_10_1186_s13045_024_01561_6 crossref_primary_10_1080_21655979_2021_1996054 crossref_primary_10_1136_bmjopen_2021_059457 crossref_primary_10_1016_j_canlet_2024_217095 crossref_primary_10_2147_CMAR_S310331 crossref_primary_10_1007_s12672_024_01530_y crossref_primary_10_1016_j_xcrm_2024_101920 crossref_primary_10_1038_s41467_023_43038_z crossref_primary_10_1186_s12885_025_13859_w crossref_primary_10_1186_s12576_024_00950_3 crossref_primary_10_1016_j_gene_2023_147704 crossref_primary_10_1038_s41598_024_69183_z crossref_primary_10_3390_ijms252011091 crossref_primary_10_1016_j_bbadis_2023_166665 crossref_primary_10_1016_j_nantod_2024_102308 crossref_primary_10_1016_j_cell_2022_10_006 crossref_primary_10_1097_MD_0000000000040574 crossref_primary_10_1155_2022_5254911 crossref_primary_10_3389_fonc_2022_811567 crossref_primary_10_1155_2021_4279039 crossref_primary_10_1016_j_gendis_2024_101450 crossref_primary_10_3389_fimmu_2024_1414376 crossref_primary_10_3390_cancers15030767 crossref_primary_10_1016_j_jconrel_2022_03_054 crossref_primary_10_1016_j_cmet_2023_07_006 crossref_primary_10_1016_j_intimp_2023_110696 crossref_primary_10_3389_fonc_2022_1070243 crossref_primary_10_1021_acsnano_2c07607 crossref_primary_10_2174_0115680096281451240306062101 crossref_primary_10_3390_cancers13205206 crossref_primary_10_1016_j_jconrel_2024_05_006 crossref_primary_10_1021_acscentsci_3c00365 crossref_primary_10_1007_s00520_022_06948_0 crossref_primary_10_1016_j_lungcan_2023_01_016 crossref_primary_10_3389_fchem_2024_1508912 crossref_primary_10_1002_cam4_3902 crossref_primary_10_1038_s41467_023_36045_7 crossref_primary_10_1038_s41598_024_77630_0 crossref_primary_10_1016_j_drudis_2020_07_014 crossref_primary_10_3389_fphar_2023_1163432 crossref_primary_10_1139_cjpp_2023_0118 crossref_primary_10_1093_hmg_ddaa137 crossref_primary_10_1111_jcmm_18003 crossref_primary_10_2174_1874471016666230526153806 crossref_primary_10_3389_fendo_2021_774244 crossref_primary_10_1186_s12885_024_13220_7 crossref_primary_10_1016_j_bioadv_2024_213996 crossref_primary_10_1038_s41467_023_37656_w crossref_primary_10_3390_molecules28073147 crossref_primary_10_3390_molecules26051392 crossref_primary_10_3389_fonc_2020_01189 crossref_primary_10_1039_D2RA05592A crossref_primary_10_1055_s_0042_1755454
Cites_doi	10.1016/S2213-2600(19)30084-0 10.1016/j.immuni.2018.03.023 10.3390/ijms19102885 10.1158/1078-0432.CCR-15-1136 10.1038/s41591-019-0592-2 10.1016/j.cell.2016.02.065 10.1158/1078-0432.CCR-15-1696 10.1038/s41591-018-0266-5 10.1016/S1470-2045(18)30673-9 10.1056/NEJMoa1609783 10.1182/blood-2016-09-738245 10.1038/nri3129 10.1016/j.cell.2017.04.014 10.1186/s40425-017-0278-6 10.1038/nm.3853 10.1016/j.cell.2018.10.038 10.1016/j.immuni.2013.07.012 10.1080/13696998.2017.1423488 10.1002/ijc.20908 10.1172/JCI58653 10.1038/s41591-018-0134-3 10.1158/2326-6066.CIR-16-0287 10.1056/NEJMoa1712126 10.1056/NEJMoa1801005 10.1038/ni1058 10.1038/s41591-018-0045-3 10.1146/annurev-med-062016-050343 10.1016/j.immuni.2016.01.024 10.1200/JCO.2015.66.1389 10.1038/nrc3245 10.1038/s41573-018-0007-y 10.1056/NEJMoa1103849 10.1200/JCO.2017.75.1644 10.1186/1471-2164-15-190 10.1097/QAD.0000000000000243 10.1093/annonc/mdz394.075 10.1016/j.cell.2018.05.060 10.1172/JCI45817 10.1186/s40425-019-0793-8 10.1038/s41573-018-0006-z 10.1158/1078-0432.CCR-18-0793 10.1158/2326-6066.CIR-16-0045 10.1126/science.aaa1348 10.1200/JCO.2016.67.9761 10.1177/1740774508091815 10.1097/01.cji.0000436722.46675.4a 10.1182/blood-2017-08-798322 10.1097/PPO.0000000000000327 10.18632/oncotarget.13895 10.1186/s40425-018-0409-8 10.1038/nature14664 10.2967/jnumed.117.195610 10.1158/2159-8290.CD-16-0828 10.1172/JCI91190 10.1016/j.ejca.2018.06.033 10.1093/annonc/mdy424.036 10.1016/S1470-2045(17)30074-8 10.1200/JCO.2016.34.15_suppl.e20665 10.1056/NEJMoa1609279 10.1186/s40425-019-0540-1 10.1038/nature13954 10.1158/1538-7445.AM2019-CT061 10.1126/science.271.5256.1734 10.1126/science.aar3593 10.1016/j.conctc.2017.09.004 10.1200/JCO.2015.64.0391 10.1158/2159-8290.CD-16-1223 10.1016/j.ejca.2018.07.127 10.1158/1078-0432.CCR-18-1316 10.1016/S0140-6736(16)00561-4 10.1016/j.bbmt.2012.04.005 10.1186/s12967-019-1847-x 10.3389/fonc.2018.00285 10.1016/0167-5699(93)90264-L 10.3322/caac.21492 10.1172/JCI34409C1 10.4049/jimmunol.160.3.1224 10.1016/S0140-6736(15)01281-7 10.1158/1078-0432.CCR-17-3662 10.1093/annonc/mdx302.003 10.1007/s11060-018-2955-9 10.1038/s41571-018-0102-3 10.1002/hep.27254 10.1200/JCO.2018.36.15_suppl.9516 10.1038/nature21349 10.1073/pnas.93.18.9730 10.1038/nature14404 10.1172/jci.insight.121522 10.1111/imr.12140 10.1093/annonc/mdy232 10.15252/emmm.201606857 10.1002/ijc.30489 10.1056/NEJMoa1801946 10.1016/j.jtho.2018.05.004 10.1093/annonc/mdx225 10.1016/S0140-6736(16)32455-2 10.1016/j.cell.2017.10.001 10.1158/1538-7445.AM2019-1267 10.1158/2326-6066.CIR-16-0060 10.1016/j.cell.2017.05.035 10.1158/1078-0432.CCR-14-2708 10.1056/NEJMoa1616288 10.1016/j.jaut.2009.08.008 10.1038/s41467-019-12160-2 10.1056/NEJMoa1707447 10.1093/annonc/mdy288.110 10.1073/pnas.2334336100 10.1016/j.semcancer.2017.12.002 10.4049/jimmunol.1701041 10.1016/j.clgc.2017.10.008 10.1097/PPO.0000000000000296 10.1126/science.aaf1490 10.3389/fimmu.2018.00070 10.1007/s10549-017-4537-5 10.1038/nature25501 10.1177/1758835918764628 10.1093/annonc/mdx755 10.1038/s41588-018-0312-8 10.1158/2326-6066.CIR-16-0114 10.1158/1078-0432.CCR-15-1507 10.1158/1535-7163.MCT-16-0157 10.1038/srep23002 10.1016/j.coi.2016.02.006 10.1126/science.aar6711 10.1056/NEJMoa1604958 10.1016/j.jtho.2018.05.013 10.1158/1078-0432.CCR-09-1624 10.1158/1078-0432.CCR-16-1946-T 10.1093/annonc/mdw217 10.1038/nature14011 10.1038/s41591-018-0053-3 10.1016/j.mrrev.2018.05.001 10.1158/2159-8290.CD-17-1327 10.3389/fonc.2013.00243 10.1172/JCI121476 10.1126/scitranslmed.aax8861 10.1056/NEJMp1709968 10.1016/S1470-2045(18)30700-9 10.1038/clpt.2009.68 10.1016/j.immuni.2011.09.021 10.1016/j.jtho.2016.11.2228 10.1056/NEJMoa1500596 10.1038/nature12477 10.1158/2326-6066.CIR-16-0325 10.1016/j.coi.2018.03.006 10.1056/NEJMoa1215134 10.1038/nrc.2016.91 10.1200/JCO.2017.35.4_suppl.673 10.1158/2326-6066.CIR-17-0292 10.1038/nature25187 10.1016/S0140-6736(16)32517-X 10.1093/jnci/88.2.100 10.1016/S1470-2045(14)71170-2 10.1056/NEJMoa1613493 10.1016/S1470-2045(19)30274-8 10.1126/science.1158545 10.1002/cpt.814 10.1056/NEJMoa1709937 10.1073/pnas.1802166115 10.1093/annonc/mdx380.017 10.1038/s41586-018-0130-2 10.1186/s13045-015-0213-6 10.3390/ijms20040999 10.1016/S1470-2045(19)30027-0 10.1056/NEJMoa1810865 10.1038/s41467-017-02424-0 10.1038/s41586-019-1032-7 10.1016/j.ccell.2014.12.001 10.1093/jnci/djw144 10.1200/JCO.2004.04.020 10.1158/1078-0432.CCR-18-3488 10.1016/j.immuni.2018.12.024 10.1016/j.ejca.2016.03.086 10.1158/2159-8290.CD-17-1320 10.1200/JCO.2014.59.1636 10.1186/s40425-018-0426-7 10.1084/jem.192.7.1027 10.1056/NEJMoa1606774 10.1093/annonc/mdz253.018 10.1093/annonc/mdz394.077
ContentType	Journal Article
Copyright	2019 Elsevier Inc. Copyright © 2019 Elsevier Inc. All rights reserved. 2019. Elsevier Inc.
Copyright_xml	– notice: 2019 Elsevier Inc. – notice: Copyright © 2019 Elsevier Inc. All rights reserved. – notice: 2019. Elsevier Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 RC3 7X8
DOI	10.1016/j.immuni.2019.12.011
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Nursing & Allied Health Premium Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Calcium & Calcified Tissue Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE Virology and AIDS Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1097-4180
EndPage	35
ExternalDocumentID	31940268 10_1016_j_immuni_2019_12_011 S1074761319305308
Genre	Journal Article Review
GroupedDBID	--- --K -DZ 0R~ 1RT 1~5 2WC 4.4 457 4G. 53G 5GY 62- 7-5 7RV 8C1 8FE 8FH AACTN AAEDW AAFTH AAIAV AAKRW AALRI AAUCE AAVLU AAXUO ABMAC ABMWF ABOCM ABVKL ACGFO ACGFS ACIWK ACPRK ADBBV ADEZE ADFRT ADJPV AEFWE AENEX AEXQZ AFRAH AFTJW AGGSO AGKMS AHMBA AITUG ALKID ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL BBNVY BENPR BKEYQ BPHCQ BVXVI C45 CS3 DIK DU5 E3Z EBS EJD F5P FCP FDB FIRID HCIFZ IH2 IHE IXB J1W JIG LK8 LX5 M2O M3Z M41 M7P N9A O-L O9- OK1 OVD P2P PQQKQ PROAC RCE ROL RPZ SCP SES SSZ TEORI TR2 WQ6 ZA5 .55 .GJ 29I 5VS AAEDT AAIKJ AAMRU AAQFI AAQXK AAYWO AAYXX ABDGV ABJNI ABWVN ACRPL ACVFH ADCNI ADMUD ADNMO ADVLN AEUPX AFPUW AGCQF AGHFR AGQPQ AHHHB AIGII AKAPO AKBMS AKRWK AKYEP APXCP CITATION FEDTE FGOYB G-2 HVGLF HZ~ OHT OZT R2- RIG UHS X7M Y6R ZGI 0SF CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 8FD C1K EFKBS FR3 H94 K9. M7N NAPCQ P64 RC3 7X8
ID	FETCH-LOGICAL-c436t-e27112f5e44fdc9b37eb851f905c8de3ead8fe2c5c277ebab0d2773562889d573
IEDL.DBID	IXB
ISSN	1074-7613 1097-4180
IngestDate	Fri Jul 11 09:52:56 EDT 2025 Fri Jul 25 11:05:25 EDT 2025 Thu Jan 02 22:58:50 EST 2025 Tue Jul 01 01:58:42 EDT 2025 Thu Apr 24 23:08:14 EDT 2025 Fri Feb 23 02:47:15 EST 2024
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	intrinsic immune resistance biomarkers CAR T adaptive immune resistance cellular therapy primary immune escape cancer immune phenotypes tumor mutational burden secondary immune escape cancer immunotherapy synthetic immunity T cell engagers immuno-oncology bispecific antibodies
Language	English
License	Copyright © 2019 Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c436t-e27112f5e44fdc9b37eb851f905c8de3ead8fe2c5c277ebab0d2773562889d573
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0001-5085-3579
OpenAccessLink	http://www.cell.com/article/S1074761319305308/pdf
PMID	31940268
PQID	2337925233
PQPubID	2031079
PageCount	19
ParticipantIDs	proquest_miscellaneous_2339792485 proquest_journals_2337925233 pubmed_primary_31940268 crossref_citationtrail_10_1016_j_immuni_2019_12_011 crossref_primary_10_1016_j_immuni_2019_12_011 elsevier_sciencedirect_doi_10_1016_j_immuni_2019_12_011
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2020-01-14
PublicationDateYYYYMMDD	2020-01-14
PublicationDate_xml	– month: 01 year: 2020 text: 2020-01-14 day: 14
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Cambridge
PublicationTitle	Immunity (Cambridge, Mass.)
PublicationTitleAlternate	Immunity
PublicationYear	2020
Publisher	Elsevier Inc Elsevier Limited
Publisher_xml	– name: Elsevier Inc – name: Elsevier Limited
References	Alexandrov, Nik-Zainal, Wedge, Aparicio, Behjati, Biankin, Bignell, Bolli, Borg, Børresen-Dale (bib1) 2013; 500 Argiles, Saro, Segal, Melero, Ros, Marabelle, Rodriguez, Albanell, Calvo, Moreno (bib5) 2017; 28 Crispe (bib32) 2014; 60 Gentilini, Pastore, Marra, Raggi (bib53) 2018; 19 Ikeda, Sung, Kudo, Kobayashi, Baron, Finn, Kaneko, Zhu, Kubota, Kralijevic (bib82) 2019; 79 Zhukovsky, Morse, Maus (bib190) 2016; 40 Barlesi, Vansteenkiste, Spigel, Ishii, Garassino, de Marinis, Özgüroğlu, Szczesna, Polychronis, Uslu (bib14) 2018; 19 Hegde, Karanikas, Evers (bib66) 2016; 22 Long, Dummer, Hamid, Gajewski, Caglevic, Dalle, Arance, Carlino, Grob, Kim (bib104) 2019; 20 Topp, Gökbuget, Stein, Zugmaier, O’Brien, Bargou, Dombret, Fielding, Heffner, Larson (bib172) 2015; 16 Dong, Sun, Zhang (bib36) 2017; 8 Hamid, Robert, Daud, Hodi, Hwu, Kefford, Wolchok, Hersey, Joseph, Weber (bib63) 2018; 36 Motzer, Penkov, Haanen, Rini, Albiges, Campbell, Kollmannsberger, Negrier, Uemura, Lee (bib117) 2018; 29 Claret, Jin, Ferte, Winter, Girish, Stroh, He, Ballinger, Sandler, Joshi (bib31) 2018; 24 Galon, Bruni (bib48) 2019; 18 Haanen, Carbonnel, Robert, Kerr, Peters, Larkin, Jordan, Committee (bib62) 2017; 28 Martin, Rizzo, Wingard, Ballen, Curtin, Cutler, Litzow, Nieto, Savani, Schriber (bib108) 2012; 18 Kowanetz, Zou, Gettinger, Koeppen, Kockx, Schmid, Kadel, Wistuba, Chaft, Rizvi (bib92) 2018; 115 Gould, Junttila, de Sauvage (bib56) 2015; 21 Nass, Rothenberg, Pentz, Hricak, Abernethy, Anderson, Gee, Harvey, Piantadosi, Bertagnolli (bib119) 2018; 15 Chong, Melenhorst, Lacey, Ambrose, Gonzalez, Levine, June, Schuster (bib30) 2017; 129 Rittmeyer, Barlesi, Waterkamp, Park, Ciardiello, von Pawel, Gadgeel, Hida, Kowalski, Dols (bib142) 2017; 389 Takahashi, Harashima, Kajigaya, Yokoyama, Cherkasova, McCoy, Hanada, Mena, Kurlander, Tawab (bib167) 2008; 118 Chen (bib24) 2017 Perea, Bernal, Sánchez-Palencia, Carretero, Torres, Bayarri, Gómez-Morales, Garrido, Ruiz-Cabello (bib128) 2017; 140 Atkins, Plimack, Puzanov, Fishman, McDermott, Cho, Vaishampayan, George, Olencki, Tarazi (bib6) 2018; 36 Fridman, Pagès, Sautès-Fridman, Galon (bib47) 2012; 12 Peters, Cho, Reinmuth, Lee, Luft, Ahn, Baas, Dols, Smolin, Vicente (bib130) 2019; 79 Chen, Hurwitz (bib26) 2018; 24 Reck, Rodríguez-Abreu, Robinson, Hui, Csőszi, Fülöp, Gottfried, Peled, Tafreshi, Cuffe (bib136) 2016; 375 Castle, Loewer, Boegel, de Graaf, Bender, Tadmor, Boisguerin, Bukur, Sorn, Paret (bib20) 2014; 15 Xiang, Gilkes (bib185) 2019; 20 Bray, Ferlay, Soerjomataram, Siegel, Torre, Jemal (bib16) 2018; 68 Sosa, Lopez Cadena, Simon Olive, Karachaliou, Rosell (bib162) 2018; 10 Shields, Jacobs, Sznol, Graham, Germain, Lum, Jaffee, de Vries, Nimmagadda, Van den Abbeele (bib155) 2018; 59 Balar, Galsky, Rosenberg, Powles, Petrylak, Bellmunt, Loriot, Necchi, Hoffman-Censits, Perez-Gracia (bib11) 2017; 389 Zloza, Karolina Palucka, Coussens, Gotwals, Headley, Jaffee, Lund, Sharpe, Sznol, Wainwright (bib192) 2017; 5 Hodi, Ballinger, Lyons, Soria, Nishino, Tabernero, Powles, Smith, Hoos, McKenna (bib75) 2018; 36 Samstein, Lee, Shoushtari, Hellmann, Shen, Janjigian, Barron, Zehir, Jordan, Omuro (bib151) 2019; 51 Ayers, Lunceford, Nebozhyn, Murphy, Loboda, Kaufman, Albright, Cheng, Kang, Shankaran (bib7) 2017; 127 Bargou, Leo, Zugmaier, Klinger, Goebeler, Knop, Noppeney, Viardot, Hess, Schuler (bib12) 2008; 321 Freeman, Long, Iwai, Bourque, Chernova, Nishimura, Fitz, Malenkovich, Okazaki, Byrne (bib45) 2000; 192 Pereira, Gimenez-Xavier, Pros, Pajares, Moro, Gomez, Navarro, Condom, Moran, Gomez-Lopez (bib129) 2017; 23 Simon (bib158) 2017; 102 Antonia, Villegas, Daniel, Vicente, Murakami, Hui, Yokoi, Chiappori, Lee, de Wit (bib3) 2017; 377 Pao, Ooi, Birzele, Ruefli-Brasse, Cannarile, Reis, Scharf, Schubert, Hatje, Pelletier (bib125) 2018; 8 Landi, D’Incà, Gelibter, Chiari, Grossi, Delmonte, Passaro, Signorelli, Gelsomino, Galetta (bib93) 2019; 7 Ebert, Cheung, Yang, McNamara, Hong, Moskalenko, Gould, Maecker, Irving, Kim (bib38) 2016; 44 Liu, Camidge, Gettinger, Giaccone, Heist, Hodi, Ready, Zhang, Wallin, Funke (bib103) 2018; 101 Tang, Shalabi, Hubbard-Lucey (bib168) 2018; 29 Spranger, Bao, Gajewski (bib193) 2015; 523 May, Gompels, Delpech, Porter, Orkin, Kegg, Hay, Johnson, Palfreeman, Gilson (bib110) 2014; 28 Faroudi, Utzny, Salio, Cerundolo, Guiraud, Müller, Valitutti (bib43) 2003; 100 Kim, Chen (bib89) 2016; 8 Purbhoo, Irvine, Huppa, Davis (bib135) 2004; 5 Reck, Mok, Nishio, Jotte, Cappuzzo, Orlandi, Stroyakovskiy, Nogami, Rodríguez-Abreu, Moro-Sibilot (bib137) 2019; 7 Pradel, Ooi, Romagnoli, Cannarile, Sade, Rüttinger, Ries (bib133) 2016; 15 McGranahan, Furness, Rosenthal, Ramskov, Lyngaa, Saini, Jamal-Hanjani, Wilson, Birkbak, Hiley (bib113) 2016; 351 Rosenthal, Cadieux, Salgado, Bakir, Moore, Hiley, Lund, Tanić, Reading, Joshi (bib147) 2019; 567 Hansen, Massard, Ott, Haas, Lopez, Ejadi, Wallmark, Keam, Delord, Aggarwal (bib65) 2018; 29 Lavin, Kobayashi, Leader, Amir, Elefant, Bigenwald, Remark, Sweeney, Becker, Levine (bib94) 2017; 169 Parsons (bib126) 2018; 777 Grasso, Giannakis, Wells, Hamada, Mu, Quist, Nowak, Nishihara, Qian, Inamura (bib58) 2018; 8 Iglesia, Parker, Hoadley, Serody, Perou, Vincent (bib81) 2016; 108 Spigel, de Marinis, Giaccone, Reinmuth, Vergnenegre, Barrios, Morise, Felip, Andric, Geater (bib164) 2019; 30 Czuczman, Weaver, Alkuzweny, Berlfein, Grillo-López (bib34) 2004; 22 Dranoff (bib37) 2011; 12 Varadarajan, Julg, Yamanaka, Chen, Ogunniyi, McAndrew, Porter, Piechocka-Trocha, Hill, Douek (bib178) 2011; 121 Robbins, Kassim, Tran, Crystal, Morgan, Feldman, Yang, Dudley, Wunderlich, Sherry (bib145) 2015; 21 McGranahan, Swanton (bib112) 2015; 27 Mosely, Prime, Sainson, Koopmann, Wang, Greenawalt, Ahdesmaki, Leyland, Mullins, Pacelli (bib116) 2017; 5 Chen, Mellman (bib27) 2013; 39 Salmon, Franciszkiewicz, Damotte, Dieu-Nosjean, Validire, Trautmann, Mami-Chouaib, Donnadieu (bib149) 2012; 122 Salmon, Remark, Gnjatic, Merad (bib150) 2019; 19 Lemery, Keegan, Pazdur (bib99) 2017; 377 Herbst, Baas, Kim, Felip, Pérez-Gracia, Han, Molina, Kim, Arvis, Ahn (bib70) 2016; 387 Pillai, Kamphorst, Owonikoko, Behera, Pakkala, Khuri, Ahmed, Ramalingam (bib194) 2016; 34 Hugo, Zaretsky, Sun, Song, Moreno, Hu-Lieskovan, Berent-Maoz, Pang, Chmielowski, Cherry (bib80) 2016; 165 Cristescu, Mogg, Ayers, Albright, Murphy, Yearley, Sher, Liu, Lu, Nebozhyn (bib33) 2018; 362 Li, Piskol, Ybarra, Chen, Li, Slaga, Hristopoulos, Clark, Modrusan, Totpal (bib100) 2019; 11 Wang, Eroglu, Ozgun, Leger, Zhao, Ye, Luke, Joseph, Haq, Ott (bib181) 2017; 5 Joshi, Robert de Massy, Ismail, Reading, Uddin, Woolston, Hatipoglu, Oakes, Rosenthal, Peacock (bib84) 2019; 25 Wolchok, Hoos, O’Day, Weber, Hamid, Lebbe, Maio, Binder, Bohnsack, Nichol (bib184) 2009; 15 Tao, Schram, Hyman (bib169) 2018; 69 Linnemann, Mezzadra, Schumacher (bib102) 2014; 257 Lukas, Rodon, Becker, Wong, Shih, Touat, Fasso, Osborne, Molinero, O’Hear (bib105) 2018; 140 Gauci, Lanoy, Champiat, Caramella, Ammari, Aspeslagh, Varga, Baldini, Bahleda, Gazzah (bib52) 2019; 25 Hirsch, McElhinny, Stanforth, Ranger-Moore, Jansson, Kulangara, Richardson, Towne, Hanks, Vennapusa (bib72) 2017; 12 Rini, Powles, Chen, Puhlmann, Atkins (bib141) 2017; 35 Weber, Hodi, Wolchok, Topalian, Schadendorf, Larkin, Sznol, Long, Li, Waxman (bib183) 2017; 35 Hellmann, Ciuleanu, Pluzanski, Lee, Otterson, Audigier-Valette, Minenza, Linardou, Burgers, Salman (bib68) 2018; 378 Freeman-Keller, Kim, Cronin, Richards, Gibney, Weber (bib46) 2016; 22 McDermott, Huseni, Atkins, Motzer, Rini, Escudier, Fong, Joseph, Pal, Reeves (bib111) 2018; 24 Guo, Zhang, Zheng, Zheng, Song, Zhang, Kang, Liu, Jin, Xing (bib61) 2018; 24 Hoffmann, Hofmeister, Brischwein, Brandl, Crommer, Bargou, Itin, Prang, Baeuerle (bib77) 2005; 115 Wang, Johnson, Davis (bib182) 2018; 24 Peters, Ramalingam, Paz-Ares, Bernabe Caro, Zurawski, Kim, Alexandru, Lupinacci, de la Mora Jimenez, Sakai (bib131) 2019; 30 Huang, Gulden, Woods, Thomas, Tong, Wang, Engelhard, Pasternack, Cotter, Hunt (bib79) 1996; 93 Olnes, Kotliarov, Biancotto, Cheung, Chen, Shi, Zhou, Wang, Tsang, Nussenblatt, Consortium (bib122) 2016; 6 Hodi, Hwu, Kefford, Weber, Daud, Hamid, Patnaik, Ribas, Robert, Gangadhar (bib74) 2016; 34 Restifo, Marincola, Kawakami, Taubenberger, Yannelli, Rosenberg (bib139) 1996; 88 Chen (bib23) 2013; 1 Oyama, Ran, Ishida, Nadaf, Kerr, Carbone, Gabrilovich (bib123) 1998; 160 Leach, Krummel, Allison (bib96) 1996; 271 Thorsson, Gibbs, Brown, Wolf, Bortone, Ou Yang, Porta-Pardo, Gao, Plaisier, Eddy (bib170) 2018; 48 Tumeh, Hellmann, Hamid, Tsai, Loo, Gubens, Rosenblum, Harview, Taube, Handley (bib177) 2017; 5 Hegde, Wallin, Mancao (bib67) 2018; 52 Schuster, Bishop, Tam, Borchmann, Jaeger, Waller, Holte, McGuirk, Jaglowski, Tobinai (bib153) 2018; 132 Lin, León (bib101) 2017; 8 Carvajal-Hausdorf, Altan, Velcheti, Gettinger, Herbst, Rimm, Schalper (bib18) 2019; 7 Garrido, Cabrera, Concha, Glew, Ruiz-Cabello, Stern (bib51) 1993; 14 Le, Uram, Wang, Bartlett, Kemberling, Eyring, Skora, Luber, Azad, Laheru (bib95) 2015; 372 Barker, Sigman, Kelloff, Hylton, Berry, Esserman (bib13) 2009; 86 Massard, Gordon, Sharma, Rafii, Wainberg, Luke, Curiel, Colon-Otero, Hamid, Sanborn (bib109) 2016; 34 Azizi, Carr, Plitas, Cornish, Konopacki, Prabhakaran, Nainys, Wu, Kiseliovas, Setty (bib9) 2018; 174 Grupp, Kalos, Barrett, Aplenc, Porter, Rheingold, Teachey, Chew, Hauck, Wright (bib60) 2013; 368 Wang, Dillon, Shi, Milasta, Carter, Finkelstein, McCormick, Fitzgerald, Chi, Munger, Green (bib180) 2011; 35 George, Lim, Jang, Cun, Ozretić, Kong, Leenders, Lu, Fernández-Cuesta, Bosco (bib54) 2015; 524 Hochster, Bendell, Cleary, Foster, Zhang, He, Hernandez, Iizuka, Eckhardt (bib73) 2017; 35 Tsao, Kerr, Kockx, Beasley, Borczuk, Botling, Bubendorf, Chirieac, Chen, Chou (bib174) 2018; 13 Eroglu, Zaretsky, Hu-Lieskovan, Kim, Algazi, Johnson, Liniker, Ben Kong, Munhoz, Rapisuwon (bib42) 2018; 553 Redman, Steinberg, Gulley (bib138) 2018; 6 Panda, de Cubas, Stein, Riedlinger, Kra, Mayer, Smith, Vincent, Serody, Beckermann (bib124) 2018; 3 Herbst, Soria, Kowanetz, Fine, Hamid, Gordon, Landi (10.1016/j.immuni.2019.12.011_bib93) 2019; 7 Lukas (10.1016/j.immuni.2019.12.011_bib105) 2018; 140 Czuczman (10.1016/j.immuni.2019.12.011_bib34) 2004; 22 Gould (10.1016/j.immuni.2019.12.011_bib56) 2015; 21 Simonsen (10.1016/j.immuni.2019.12.011_bib160) 2018; 103 Antonia (10.1016/j.immuni.2019.12.011_bib3) 2017; 377 Kersten (10.1016/j.immuni.2019.12.011_bib88) 2017; 9 Tumeh (10.1016/j.immuni.2019.12.011_bib176) 2014; 515 Fridman (10.1016/j.immuni.2019.12.011_bib47) 2012; 12 Long (10.1016/j.immuni.2019.12.011_bib104) 2019; 20 Motzer (10.1016/j.immuni.2019.12.011_bib118) 2018; 378 Leach (10.1016/j.immuni.2019.12.011_bib96) 1996; 271 Peters (10.1016/j.immuni.2019.12.011_bib130) 2019; 79 Chen (10.1016/j.immuni.2019.12.011_bib27) 2013; 39 Varadarajan (10.1016/j.immuni.2019.12.011_bib178) 2011; 121 Kowanetz (10.1016/j.immuni.2019.12.011_bib92) 2018; 115 Crispe (10.1016/j.immuni.2019.12.011_bib32) 2014; 60 Sosa (10.1016/j.immuni.2019.12.011_bib162) 2018; 10 Mellman (10.1016/j.immuni.2019.12.011_bib115) 2016; 4 Li (10.1016/j.immuni.2019.12.011_bib100) 2019; 11 Dirix (10.1016/j.immuni.2019.12.011_bib35) 2018; 167 Cristescu (10.1016/j.immuni.2019.12.011_bib33) 2018; 362 Linnemann (10.1016/j.immuni.2019.12.011_bib102) 2014; 257 Bacac (10.1016/j.immuni.2019.12.011_bib10) 2016; 22 Chawla (10.1016/j.immuni.2019.12.011_bib22) 2018; 21 Zitvogel (10.1016/j.immuni.2019.12.011_bib191) 2016; 16 Aptsiauri (10.1016/j.immuni.2019.12.011_bib4) 2018; 51 Liu (10.1016/j.immuni.2019.12.011_bib103) 2018; 101 Smith (10.1016/j.immuni.2019.12.011_bib161) 2018; 128 Eroglu (10.1016/j.immuni.2019.12.011_bib42) 2018; 553 McDermott (10.1016/j.immuni.2019.12.011_bib111) 2018; 24 Dong (10.1016/j.immuni.2019.12.011_bib36) 2017; 8 Mariathasan (10.1016/j.immuni.2019.12.011_bib107) 2018; 554 Shields (10.1016/j.immuni.2019.12.011_bib155) 2018; 59 Riley (10.1016/j.immuni.2019.12.011_bib140) 2019; 18 Argiles (10.1016/j.immuni.2019.12.011_bib5) 2017; 28 Wang (10.1016/j.immuni.2019.12.011_bib182) 2018; 24 Kim (10.1016/j.immuni.2019.12.011_bib89) 2016; 8 Alexandrov (10.1016/j.immuni.2019.12.011_bib1) 2013; 500 Garrido (10.1016/j.immuni.2019.12.011_bib51) 1993; 14 Reck (10.1016/j.immuni.2019.12.011_bib137) 2019; 7 Lin (10.1016/j.immuni.2019.12.011_bib101) 2017; 8 Olnes (10.1016/j.immuni.2019.12.011_bib122) 2016; 6 Flippot (10.1016/j.immuni.2019.12.011_bib44) 2016; 61 Chen (10.1016/j.immuni.2019.12.011_bib28) 2017; 541 Freeman-Keller (10.1016/j.immuni.2019.12.011_bib46) 2016; 22 Grupp (10.1016/j.immuni.2019.12.011_bib60) 2013; 368 Robbins (10.1016/j.immuni.2019.12.011_bib145) 2015; 21 George (10.1016/j.immuni.2019.12.011_bib54) 2015; 524 Neelapu (10.1016/j.immuni.2019.12.011_bib120) 2017; 377 Oyama (10.1016/j.immuni.2019.12.011_bib123) 1998; 160 Wang (10.1016/j.immuni.2019.12.011_bib180) 2011; 35 Zhukovsky (10.1016/j.immuni.2019.12.011_bib190) 2016; 40 Hegde (10.1016/j.immuni.2019.12.011_bib67) 2018; 52 Barker (10.1016/j.immuni.2019.12.011_bib13) 2009; 86 Salmon (10.1016/j.immuni.2019.12.011_bib150) 2019; 19 Freeman (10.1016/j.immuni.2019.12.011_bib45) 2000; 192 Herbst (10.1016/j.immuni.2019.12.011_bib70) 2016; 387 Lechner (10.1016/j.immuni.2019.12.011_bib97) 2013; 36 Motzer (10.1016/j.immuni.2019.12.011_bib117) 2018; 29 Spigel (10.1016/j.immuni.2019.12.011_bib164) 2019; 30 Takahashi (10.1016/j.immuni.2019.12.011_bib167) 2008; 118 Shin (10.1016/j.immuni.2019.12.011_bib156) 2017; 7 Hoffmann (10.1016/j.immuni.2019.12.011_bib77) 2005; 115 McGranahan (10.1016/j.immuni.2019.12.011_bib113) 2016; 351 Tran (10.1016/j.immuni.2019.12.011_bib173) 2016; 375 Reck (10.1016/j.immuni.2019.12.011_bib136) 2016; 375 Simoni (10.1016/j.immuni.2019.12.011_bib159) 2018; 557 Sugiura (10.1016/j.immuni.2019.12.011_bib166) 2018; 200 Tsimberidou (10.1016/j.immuni.2019.12.011_bib175) 2018; 6 Hodi (10.1016/j.immuni.2019.12.011_bib75) 2018; 36 Zhou (10.1016/j.immuni.2019.12.011_bib189) 2019; 50 Herbst (10.1016/j.immuni.2019.12.011_bib71) 2019; 30 Perea (10.1016/j.immuni.2019.12.011_bib128) 2017; 140 Cary (10.1016/j.immuni.2019.12.011_bib19) 2018; 16 Hellmann (10.1016/j.immuni.2019.12.011_bib68) 2018; 378 Jotte (10.1016/j.immuni.2019.12.011_bib85) 2018; 36 Botticelli (10.1016/j.immuni.2019.12.011_bib15) 2019; 17 Efremova (10.1016/j.immuni.2019.12.011_bib40) 2018; 9 Iglesia (10.1016/j.immuni.2019.12.011_bib81) 2016; 108 Ayers (10.1016/j.immuni.2019.12.011_bib7) 2017; 127 Martin (10.1016/j.immuni.2019.12.011_bib108) 2012; 18 Rosenberg (10.1016/j.immuni.2019.12.011_bib146) 2016; 387 Chau (10.1016/j.immuni.2019.12.011_bib21) 2018; 29 Ikeda (10.1016/j.immuni.2019.12.011_bib82) 2019; 79 Balar (10.1016/j.immuni.2019.12.011_bib11) 2017; 389 Pui (10.1016/j.immuni.2019.12.011_bib134) 2015; 33 Galon (10.1016/j.immuni.2019.12.011_bib48) 2019; 18 Sade-Feldman (10.1016/j.immuni.2019.12.011_bib148) 2018; 175 Panda (10.1016/j.immuni.2019.12.011_bib124) 2018; 3 Bray (10.1016/j.immuni.2019.12.011_bib16) 2018; 68 Zaretsky (10.1016/j.immuni.2019.12.011_bib186) 2016; 375 Dranoff (10.1016/j.immuni.2019.12.011_bib37) 2011; 12 Hamid (10.1016/j.immuni.2019.12.011_bib63) 2018; 36 Köhnke (10.1016/j.immuni.2019.12.011_bib91) 2015; 8 May (10.1016/j.immuni.2019.12.011_bib110) 2014; 28 Rizvi (10.1016/j.immuni.2019.12.011_bib144) 2018; 29 Grasso (10.1016/j.immuni.2019.12.011_bib58) 2018; 8 Parsons (10.1016/j.immuni.2019.12.011_bib126) 2018; 777 Thorsson (10.1016/j.immuni.2019.12.011_bib170) 2018; 48 Spranger (10.1016/j.immuni.2019.12.011_bib193) 2015; 523 Castle (10.1016/j.immuni.2019.12.011_bib20) 2014; 15 Kobold (10.1016/j.immuni.2019.12.011_bib90) 2018; 8 Rini (10.1016/j.immuni.2019.12.011_bib141) 2017; 35 Rittmeyer (10.1016/j.immuni.2019.12.011_bib142) 2017; 389 Spigel (10.1016/j.immuni.2019.12.011_bib163) 2018; 13 Chong (10.1016/j.immuni.2019.12.011_bib30) 2017; 129 Cherkasova (10.1016/j.immuni.2019.12.011_bib29) 2013; 3 Hochster (10.1016/j.immuni.2019.12.011_bib73) 2017; 35 Rizvi (10.1016/j.immuni.2019.12.011_bib143) 2015; 348 Ebert (10.1016/j.immuni.2019.12.011_bib38) 2016; 44 Restifo (10.1016/j.immuni.2019.12.011_bib139) 1996; 88 Salmon (10.1016/j.immuni.2019.12.011_bib149) 2012; 122 Massard (10.1016/j.immuni.2019.12.011_bib109) 2016; 34 Mosely (10.1016/j.immuni.2019.12.011_bib116) 2017; 5 von Pawel (10.1016/j.immuni.2019.12.011_bib179) 2017; 28 June (10.1016/j.immuni.2019.12.011_bib86) 2018; 359 Samstein (10.1016/j.immuni.2019.12.011_bib151) 2019; 51 Atkins (10.1016/j.immuni.2019.12.011_bib6) 2018; 36 McGranahan (10.1016/j.immuni.2019.12.011_bib114) 2017; 171 Paz-Ares (10.1016/j.immuni.2019.12.011_bib127) 2018; 379 Lavin (10.1016/j.immuni.2019.12.011_bib94) 2017; 169 Chen (10.1016/j.immuni.2019.12.011_bib23) 2013; 1 Hodi (10.1016/j.immuni.2019.12.011_bib76) 2018; 19 Nass (10.1016/j.immuni.2019.12.011_bib119) 2018; 15 Peters (10.1016/j.immuni.2019.12.011_bib131) 2019; 30 Hugo (10.1016/j.immuni.2019.12.011_bib80) 2016; 165 Faroudi (10.1016/j.immuni.2019.12.011_bib43) 2003; 100 Griss (10.1016/j.immuni.2019.12.011_bib59) 2019; 10 Zheng (10.1016/j.immuni.2019.12.011_bib187) 2017; 169 Wolchok (10.1016/j.immuni.2019.12.011_bib184) 2009; 15 Claret (10.1016/j.immuni.2019.12.011_bib31) 2018; 24 Carbone (10.1016/j.immuni.2019.12.011_bib17) 2017; 376 Guo (10.1016/j.immuni.2019.12.011_bib61) 2018; 24 Hansen (10.1016/j.immuni.2019.12.011_bib65) 2018; 29 Gandhi (10.1016/j.immuni.2019.12.011_bib50) 2018; 378 Chen (10.1016/j.immuni.2019.12.011_bib26) 2018; 24 Rosenthal (10.1016/j.immuni.2019.12.011_bib147) 2019; 567 Huang (10.1016/j.immuni.2019.12.011_bib79) 1996; 93 Wang (10.1016/j.immuni.2019.12.011_bib181) 2017; 5 Gauci (10.1016/j.immuni.2019.12.011_bib52) 2019; 25 Tang (10.1016/j.immuni.2019.12.011_bib168) 2018; 29 Tiegs (10.1016/j.immuni.2019.12.011_bib171) 2010; 34 Eng (10.1016/j.immuni.2019.12.011_bib41) 2019; 20 Redman (10.1016/j.immuni.2019.12.011_bib138) 2018; 6 Pao (10.1016/j.immuni.2019.12.011_bib125) 2018; 8 Xiang (10.1016/j.immuni.2019.12.011_bib185) 2019; 20 Homet Moreno (10.1016/j.immuni.2019.12.011_bib78) 2016; 4 Topp (10.1016/j.immuni.2019.12.011_bib172) 2015; 16 Weber (10.1016/j.immuni.2019.12.011_bib183) 2017; 35 Gentilini (10.1016/j.immuni.2019.12.011_bib53) 2018; 19 Pillai (10.1016/j.immuni.2019.12.011_bib194) 2016; 34 Scheper (10.1016/j.immuni.2019.12.011_bib152) 2019; 25 Zloza (10.1016/j.immuni.2019.12.011_bib192) 2017; 5 McGranahan (10.1016/j.immuni.2019.12.011_bib112) 2015; 27 Shrimali (10.1016/j.immuni.2019.12.011_bib157) 2017; 5 Seymour (10.1016/j.immuni.2019.12.011_bib154) 2017; 18 Barlesi (10.1016/j.immuni.2019.12.011_bib14) 2018; 19 Hirsch (10.1016/j.immuni.2019.12.011_bib72) 2017; 12 Pereira (10.1016/j.immuni.2019.12.011_bib129) 2017; 23 Hamid (10.1016/j.immuni.2019.12.011_bib64) 2019; 25 Jamal-Hanjani (10.1016/j.immuni.2019.12.011_bib83) 2017; 376 Anagnostou (10.1016/j.immuni.2019.12.011_bib2) 2017; 7 Lee (10.1016/j.immuni.2019.12.011_bib98) 2019; 30 Carvajal-Hausdorf (10.1016/j.immuni.2019.12.011_bib18) 2019; 7 Tao (10.1016/j.immuni.2019.12.011_bib169) 2018; 69 Bargou (10.1016/j.immuni.2019.12.011_bib12) 2008; 321 Gandara (10.1016/j.immuni.2019.12.011_bib49) 2018; 24 Porter (10.1016/j.immuni.2019.12.011_bib132) 2011; 365 Spranger (10.1016/j.immuni.2019.12.011_bib165) 2014; 2 Le (10.1016/j.immuni.2019.12.011_bib95) 2015; 372 Lemery (10.1016/j.immuni.2019.12.011_bib99) 2017; 377 Simon (10.1016/j.immuni.2019.12.011_bib158) 2017; 102 Zhou (10.1016/j.immuni.2019.12.011_bib188) 2008; 5 Ayers (10.1016/j.immuni.2019.12.011_bib8) 2019; 25 Tsao (10.1016/j.immuni.2019.12.011_bib174) 2018; 13 Oliver (10.1016/j.immuni.2019.12.011_bib121) 2018; 9 Chen (10.1016/j.immuni.2019.12.011_bib24) 2017 Ebrahimi-Nik (10.1016/j.immuni.2019.12.011_bib39) 2019; 5 Pradel (10.1016/j.immuni.2019.12.011_bib133) 2016; 15 Marabelle (10.1016/j.immuni.2019.12.011_bib106) 2019; 30 Purbhoo (10.1016/j.immuni.2019.12.011_bib135) 2004; 5 Azizi (10.1016/j.immuni.2019.12.011_bib9) 2018; 174 Tumeh (10.1016/j.immuni.2019.12.011_bib177) 2017; 5 Hegde (10.1016/j.immuni.2019.12.011_bib66) 2016; 22 Schuster (10.1016/j.immuni.2019.12.011_bib153) 2018; 132 Herbst (10.1016/j.immuni.2019.12.011_bib69) 2014; 515 Hodi (10.1016/j.immuni.2019.12.011_bib74) 2016; 34 Graeber (10.1016/j.immuni.2019.12.011_bib57) 2019 Joshi (10.1016/j.i
References_xml	– volume: 7 start-page: 65 year: 2019 ident: bib18 article-title: Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) publication-title: J. Immunother. Cancer – volume: 35 year: 2017 ident: bib141 article-title: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC) publication-title: J. Clin. Ontol. – volume: 36 year: 2018 ident: bib6 article-title: Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC) publication-title: Journal of Clinial Onocology – volume: 35 start-page: 871 year: 2011 end-page: 882 ident: bib180 article-title: The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation publication-title: Immunity – volume: 69 start-page: 319 year: 2018 end-page: 331 ident: bib169 article-title: Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology publication-title: Annu. Rev. Med. – volume: 33 start-page: 2938 year: 2015 end-page: 2948 ident: bib134 article-title: Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration publication-title: J. Clin. Oncol. – volume: 30 start-page: v851 year: 2019 end-page: v934 ident: bib98 article-title: Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, hepatocellular carcinoma (HCC). ESMO 2019 Congress publication-title: Ann. Oncol. – volume: 257 start-page: 72 year: 2014 end-page: 82 ident: bib102 article-title: TCR repertoires of intratumoral T-cell subsets publication-title: Immunol. Rev. – volume: 8 start-page: 395 year: 2018 end-page: 402 ident: bib125 article-title: Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer publication-title: Cancer Discov. – volume: 28 year: 2017 ident: bib5 article-title: Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC) publication-title: Ann. Oncol. – volume: 378 start-page: 2078 year: 2018 end-page: 2092 ident: bib50 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N. Engl. J. Med. – volume: 23 start-page: 3203 year: 2017 end-page: 3213 ident: bib129 article-title: Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition publication-title: Clin. Cancer Res – volume: 13 start-page: 1302 year: 2018 end-page: 1311 ident: bib174 article-title: PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project publication-title: J. Thorac Oncol. – volume: 44 start-page: 609 year: 2016 end-page: 621 ident: bib38 article-title: MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade publication-title: Immunity – volume: 101 start-page: 114 year: 2018 end-page: 122 ident: bib103 article-title: Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer publication-title: Eur. J. Cancer – volume: 9 start-page: 137 year: 2017 end-page: 153 ident: bib88 article-title: Genetically engineered mouse models in oncology research and cancer medicine publication-title: EMBO Mol. Med. – volume: 15 start-page: 777 year: 2018 end-page: 786 ident: bib119 article-title: Accelerating anticancer drug development - opportunities and trade-offs publication-title: Nat. Rev. Clin. Oncol. – volume: 15 year: 2014 ident: bib20 article-title: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma publication-title: BMC Genomics – volume: 368 start-page: 1509 year: 2013 end-page: 1518 ident: bib60 article-title: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia publication-title: N. Engl. J. Med. – volume: 387 start-page: 1540 year: 2016 end-page: 1550 ident: bib70 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet – volume: 128 start-page: 4804 year: 2018 end-page: 4820 ident: bib161 article-title: Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma publication-title: J. Clin. Invest. – volume: 68 start-page: 394 year: 2018 end-page: 424 ident: bib16 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. – volume: 515 start-page: 568 year: 2014 end-page: 571 ident: bib176 article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance publication-title: Nature – volume: 93 start-page: 9730 year: 1996 end-page: 9735 ident: bib79 article-title: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product publication-title: Proc. Natl. Acad. Sci. USA – volume: 103 start-page: 259 year: 2018 end-page: 266 ident: bib160 article-title: The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies publication-title: Eur. J. Cancer – volume: 10 start-page: 4186 year: 2019 ident: bib59 article-title: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma publication-title: Nat. Commun. – volume: 29 start-page: 1807 year: 2018 end-page: 1813 ident: bib65 article-title: Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study publication-title: Ann. Oncol. – volume: 8 start-page: 147 year: 2017 end-page: 155 ident: bib101 article-title: Estimation of treatment effects in weighted log-rank tests publication-title: Contemp. Clin. Trials Commun. – volume: 22 start-page: 4711 year: 2004 end-page: 4716 ident: bib34 article-title: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up publication-title: J. Clin. Oncol. – volume: 28 start-page: mdx380.017 year: 2017 ident: bib179 article-title: 1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK publication-title: Ann. Oncol. – volume: 9 start-page: 70 year: 2018 ident: bib121 article-title: Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses publication-title: Front. Immunol. – volume: 378 start-page: 1277 year: 2018 end-page: 1290 ident: bib118 article-title: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma publication-title: N. Engl. J. Med. – volume: 567 start-page: 479 year: 2019 end-page: 485 ident: bib147 article-title: Neoantigen-directed immune escape in lung cancer evolution publication-title: Nature – volume: 4 start-page: 845 year: 2016 end-page: 857 ident: bib78 article-title: Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells publication-title: Cancer Immunol. Res. – volume: 52 start-page: 117 year: 2018 end-page: 124 ident: bib67 article-title: Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics publication-title: Semin. Cancer Biol. – volume: 375 start-page: 2255 year: 2016 end-page: 2262 ident: bib173 article-title: T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer publication-title: N. Engl. J. Med. – volume: 86 start-page: 97 year: 2009 end-page: 100 ident: bib13 article-title: I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy publication-title: Clin. Pharmacol. Ther. – volume: 554 start-page: 544 year: 2018 end-page: 548 ident: bib107 article-title: TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells publication-title: Nature – volume: 11 start-page: eaax8861 year: 2019 ident: bib100 article-title: CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity publication-title: Sci. Transl. Med. – volume: 34 start-page: 1510 year: 2016 end-page: 1517 ident: bib74 article-title: Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab publication-title: J. Clin. Oncol. – volume: 9 start-page: 32 year: 2018 ident: bib40 article-title: Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution publication-title: Nat. Commun – volume: 5 start-page: 29 year: 2017 end-page: 41 ident: bib116 article-title: Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery publication-title: Cancer Immunol. Res. – volume: 5 year: 2019 ident: bib39 article-title: Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection publication-title: JCI Insight – volume: 21 start-page: 431 year: 2015 end-page: 439 ident: bib56 article-title: Translational value of mouse models in oncology drug development publication-title: Nat. Med. – volume: 24 start-page: 1441 year: 2018 end-page: 1448 ident: bib49 article-title: Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab publication-title: Nat. Med. – volume: 30 start-page: v475 year: 2019 end-page: v532 ident: bib106 article-title: Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. ESMO 2019 Congress publication-title: Ann. Oncol. – volume: 24 start-page: 36 year: 2018 end-page: 40 ident: bib182 article-title: Toxicities Associated With PD-1/PD-L1 Blockade publication-title: Cancer J. – volume: 359 start-page: 1361 year: 2018 end-page: 1365 ident: bib86 article-title: CAR T cell immunotherapy for human cancer publication-title: Science – volume: 387 start-page: 1909 year: 2016 end-page: 1920 ident: bib146 article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial publication-title: Lancet – volume: 88 start-page: 100 year: 1996 end-page: 108 ident: bib139 article-title: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy publication-title: J. Natl. Cancer Inst. – volume: 14 start-page: 491 year: 1993 end-page: 499 ident: bib51 article-title: Natural history of HLA expression during tumour development publication-title: Immunol. Today – volume: 200 start-page: 400 year: 2018 end-page: 407 ident: bib166 article-title: Metabolic Barriers to T Cell Function in Tumors publication-title: J. Immunol. – volume: 169 start-page: 1342 year: 2017 end-page: 1356.e16 ident: bib187 article-title: Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing publication-title: Cell – volume: 25 start-page: 946 year: 2019 end-page: 956 ident: bib52 article-title: Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation publication-title: Clin. Cancer Res. – volume: 372 start-page: 2509 year: 2015 end-page: 2520 ident: bib95 article-title: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency publication-title: N. Engl. J. Med. – volume: 40 start-page: 24 year: 2016 end-page: 35 ident: bib190 article-title: Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection publication-title: Curr. Opin. Immunol. – volume: 365 start-page: 725 year: 2011 end-page: 733 ident: bib132 article-title: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia publication-title: N. Engl. J. Med. – volume: 21 start-page: 1019 year: 2015 end-page: 1027 ident: bib145 article-title: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response publication-title: Clin. Cancer Res. – volume: 376 start-page: 2415 year: 2017 end-page: 2426 ident: bib17 article-title: First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. – volume: 121 start-page: 4322 year: 2011 end-page: 4331 ident: bib178 article-title: A high-throughput single-cell analysis of human CD8 publication-title: J. Clin. Invest. – volume: 17 start-page: 99 year: 2019 ident: bib15 article-title: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab publication-title: J. Transl. Med. – volume: 12 start-page: 61 year: 2011 end-page: 66 ident: bib37 article-title: Experimental mouse tumour models: what can be learnt about human cancer immunology? publication-title: Nat. Rev. Immunol. – volume: 36 year: 2018 ident: bib63 article-title: 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001 publication-title: J. Clin. Oncol. – volume: 30 start-page: v851 year: 2019 end-page: v934 ident: bib71 article-title: Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and –042 trials publication-title: Ann. Oncol. – volume: 35 start-page: 673 year: 2017 ident: bib73 article-title: Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC) publication-title: J. Clin. Oncol. – volume: 524 start-page: 47 year: 2015 end-page: 53 ident: bib54 article-title: Comprehensive genomic profiles of small cell lung cancer publication-title: Nature – volume: 16 start-page: 759 year: 2016 end-page: 773 ident: bib191 article-title: Mouse models in oncoimmunology publication-title: Nat. Rev. Cancer – volume: 362 start-page: eaar3593 year: 2018 ident: bib33 article-title: Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy publication-title: Science – volume: 20 start-page: 849 year: 2019 end-page: 861 ident: bib41 article-title: Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial publication-title: Lancet Oncol. – volume: 8 start-page: 111 year: 2015 ident: bib91 article-title: Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab publication-title: J. Hematol. Oncol. – volume: 115 start-page: E10119 year: 2018 end-page: E10126 ident: bib92 article-title: Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) publication-title: Proc. Natl. Acad. Sci. USA – volume: 20 start-page: 1083 year: 2019 end-page: 1097 ident: bib104 article-title: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study publication-title: Lancet Oncol. – volume: 557 start-page: 575 year: 2018 end-page: 579 ident: bib159 article-title: Bystander CD8 publication-title: Nature – volume: 129 start-page: 1039 year: 2017 end-page: 1041 ident: bib30 article-title: PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR publication-title: Blood – volume: 24 start-page: 978 year: 2018 end-page: 985 ident: bib61 article-title: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing publication-title: Nat. Med. – volume: 29 year: 2018 ident: bib117 article-title: LBA6_PRJAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) publication-title: Ann. Oncol. – volume: 118 start-page: 1099 year: 2008 end-page: 1109 ident: bib167 article-title: Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells publication-title: J. Clin. Invest. – volume: 377 start-page: 1409 year: 2017 end-page: 1412 ident: bib99 article-title: First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication publication-title: N. Engl. J. Med. – volume: 61 start-page: 61 year: 2016 end-page: 68 ident: bib44 article-title: Oncogenic viruses: Lessons learned using next-generation sequencing technologies publication-title: Eur. J. Cancer – volume: 30 start-page: v851 year: 2019 end-page: v934 ident: bib131 article-title: Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis publication-title: Ann. Oncol. – volume: 50 start-page: 403 year: 2019 end-page: 417.e4 ident: bib189 article-title: Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis publication-title: Immunity – volume: 8 start-page: 730 year: 2018 end-page: 749 ident: bib58 article-title: Genetic Mechanisms of Immune Evasion in Colorectal Cancer publication-title: Cancer Discov. – volume: 34 start-page: 1 year: 2010 end-page: 6 ident: bib171 article-title: Immune tolerance: what is unique about the liver publication-title: J. Autoimmun. – volume: 13 start-page: 1733 year: 2018 end-page: 1742 ident: bib163 article-title: FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC publication-title: J. Thorac. Oncol. – volume: 375 start-page: 1823 year: 2016 end-page: 1833 ident: bib136 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N. Engl. J. Med. – volume: 27 start-page: 15 year: 2015 end-page: 26 ident: bib112 article-title: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution publication-title: Cancer Cell – volume: 2 year: 2014 ident: bib165 article-title: Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment publication-title: J. Immunother. Cancer – volume: 48 start-page: 812 year: 2018 end-page: 830.e14 ident: bib170 article-title: The Immune Landscape of Cancer publication-title: Immunity – volume: 34 year: 2016 ident: bib194 article-title: Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC) publication-title: J. Clin. Oncol. – volume: 271 start-page: 1734 year: 1996 end-page: 1736 ident: bib96 article-title: Enhancement of antitumor immunity by CTLA-4 blockade publication-title: Science – volume: 51 start-page: 123 year: 2018 end-page: 132 ident: bib4 article-title: The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses publication-title: Curr. Opin. Immunol. – volume: 377 start-page: 2531 year: 2017 end-page: 2544 ident: bib120 article-title: Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma publication-title: N. Engl. J. Med. – volume: 174 start-page: 1293 year: 2018 end-page: 1308.e36 ident: bib9 article-title: Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment publication-title: Cell – volume: 127 start-page: 2930 year: 2017 end-page: 2940 ident: bib7 article-title: IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade publication-title: J. Clin. Invest. – volume: 28 start-page: iv119 year: 2017 end-page: iv142 ident: bib62 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. – volume: 3 start-page: 121522 year: 2018 ident: bib124 article-title: Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma publication-title: JCI Insight – volume: 376 start-page: 2109 year: 2017 end-page: 2121 ident: bib83 article-title: Tracking the Evolution of Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. – volume: 29 start-page: 84 year: 2018 end-page: 91 ident: bib168 article-title: Comprehensive analysis of the clinical immuno-oncology landscape publication-title: Ann. Oncol. – volume: 108 year: 2016 ident: bib81 article-title: Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types publication-title: J. Natl. Cancer Inst. – volume: 102 start-page: 934 year: 2017 end-page: 941 ident: bib158 article-title: Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials publication-title: Clin. Pharmacol. Ther. – volume: 25 start-page: 6061 year: 2019 end-page: 6072 ident: bib64 article-title: Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab publication-title: Clin. Cancer Res. – year: 2019 ident: bib57 article-title: The Breakthrough: Immunotherapy and the Race to Cure Cancer – volume: 25 start-page: 89 year: 2019 end-page: 94 ident: bib152 article-title: Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers publication-title: Nat. Med. – volume: 5 start-page: 524 year: 2004 end-page: 530 ident: bib135 article-title: T cell killing does not require the formation of a stable mature immunological synapse publication-title: Nat. Immunol. – volume: 22 start-page: 886 year: 2016 end-page: 894 ident: bib46 article-title: Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes publication-title: Clin. Cancer Res. – volume: 16 start-page: 57 year: 2015 end-page: 66 ident: bib172 article-title: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study publication-title: Lancet Oncol. – volume: 21 start-page: 543 year: 2018 end-page: 552 ident: bib22 article-title: Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers publication-title: J. Med. Econ. – volume: 18 start-page: 175 year: 2019 end-page: 196 ident: bib140 article-title: Delivery technologies for cancer immunotherapy publication-title: Nat. Rev. Drug Discov. – volume: 140 start-page: 317 year: 2018 end-page: 328 ident: bib105 article-title: Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma publication-title: J. Neurooncol. – volume: 351 start-page: 1463 year: 2016 end-page: 1469 ident: bib113 article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade publication-title: Science – volume: 18 start-page: 197 year: 2019 end-page: 218 ident: bib48 article-title: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies publication-title: Nat. Rev. Drug Discov. – volume: 7 start-page: 316 year: 2019 ident: bib93 article-title: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer publication-title: J. Immunother. Cancer – volume: 348 start-page: 124 year: 2015 end-page: 128 ident: bib143 article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer publication-title: Science – volume: 777 start-page: 1 year: 2018 end-page: 18 ident: bib126 article-title: Multiclonal tumor origin: Evidence and implications publication-title: Mutat. Res. – volume: 171 start-page: 1259 year: 2017 end-page: 1271.e11 ident: bib114 article-title: Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution publication-title: Cell – volume: 6 start-page: 108 year: 2018 ident: bib175 article-title: Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement publication-title: J. Immunother. Cancer – volume: 115 start-page: 98 year: 2005 end-page: 104 ident: bib77 article-title: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct publication-title: Int. J. Cancer – volume: 100 start-page: 14145 year: 2003 end-page: 14150 ident: bib43 article-title: Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold publication-title: Proc. Natl. Acad. Sci. USA – volume: 36 start-page: 477 year: 2013 end-page: 489 ident: bib97 article-title: Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy publication-title: J. Immunother. – volume: 36 year: 2018 ident: bib85 article-title: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC publication-title: J. Clin. Ontol. – volume: 24 start-page: 3292 year: 2018 end-page: 3298 ident: bib31 article-title: A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics publication-title: Clin. Cancer Res – volume: 132 year: 2018 ident: bib153 article-title: Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel publication-title: Blood – volume: 165 start-page: 35 year: 2016 end-page: 44 ident: bib80 article-title: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma publication-title: Cell – volume: 160 start-page: 1224 year: 1998 end-page: 1232 ident: bib123 article-title: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells publication-title: J. Immunol. – volume: 16 start-page: e307 year: 2018 end-page: e313 ident: bib19 article-title: Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution publication-title: Clin. Genitourin. Cancer – volume: 4 start-page: 279 year: 2016 end-page: 288 ident: bib115 article-title: De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute publication-title: Cancer Immunol. Res. – volume: 24 start-page: 193 year: 2018 end-page: 204 ident: bib26 article-title: Combinations of Bevacizumab With Cancer Immunotherapy publication-title: Cancer J. – volume: 167 start-page: 671 year: 2018 end-page: 686 ident: bib35 article-title: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study publication-title: Breast Cancer Res. Treat. – volume: 192 start-page: 1027 year: 2000 end-page: 1034 ident: bib45 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. – volume: 389 start-page: 255 year: 2017 end-page: 265 ident: bib142 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet – volume: 15 start-page: 3077 year: 2016 end-page: 3086 ident: bib133 article-title: Macrophage Susceptibility to Emactuzumab (RG7155) Treatment publication-title: Mol. Cancer Ther. – volume: 60 start-page: 2109 year: 2014 end-page: 2117 ident: bib32 article-title: Immune tolerance in liver disease publication-title: Hepatology – volume: 5 start-page: 755 year: 2017 end-page: 766 ident: bib157 article-title: Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis publication-title: Cancer Immunol. Res. – volume: 515 start-page: 563 year: 2014 end-page: 567 ident: bib69 article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients publication-title: Nature – volume: 376 start-page: 836 year: 2017 end-page: 847 ident: bib87 article-title: Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia publication-title: N. Engl. J. Med. – volume: 377 start-page: 1919 year: 2017 end-page: 1929 ident: bib3 article-title: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. – volume: 29 start-page: x39 year: 2018 end-page: x43 ident: bib144 article-title: LBA6 Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. ESMO Immuno-Oncology Congress 2018Ann publication-title: Oncol. – volume: 523 start-page: 231 year: 2015 end-page: 235 ident: bib193 article-title: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity publication-title: Nature – volume: 22 start-page: 3286 year: 2016 end-page: 3297 ident: bib10 article-title: A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors publication-title: Clin. Cancer Res – volume: 553 start-page: 347 year: 2018 end-page: 350 ident: bib42 article-title: High response rate to PD-1 blockade in desmoplastic melanomas publication-title: Nature – volume: 500 start-page: 415 year: 2013 end-page: 421 ident: bib1 article-title: Signatures of mutational processes in human cancer publication-title: Nature – volume: 375 start-page: 819 year: 2016 end-page: 829 ident: bib186 article-title: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma publication-title: N. Engl. J. Med. – volume: 131 start-page: 1522 year: 2018 end-page: 1531 ident: bib55 article-title: Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia publication-title: Blood – volume: 321 start-page: 974 year: 2008 end-page: 977 ident: bib12 article-title: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody publication-title: Science – volume: 169 start-page: 750 year: 2017 end-page: 765.e17 ident: bib94 article-title: Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses publication-title: Cell – volume: 10 year: 2018 ident: bib162 article-title: Clinical assessment of immune-related adverse events publication-title: Ther. Adv. Med. Oncol. – volume: 5 start-page: 357 year: 2017 end-page: 362 ident: bib181 article-title: Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma publication-title: Cancer Immunol. Res. – volume: 7 start-page: 264 year: 2017 end-page: 276 ident: bib2 article-title: Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer publication-title: Cancer Discov. – volume: 18 start-page: e143 year: 2017 end-page: e152 ident: bib154 article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics publication-title: Lancet Oncol. – volume: 5 start-page: 181 year: 2008 end-page: 193 ident: bib188 article-title: Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine publication-title: Clin. Trials – volume: 19 start-page: 1468 year: 2018 end-page: 1479 ident: bib14 article-title: Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study publication-title: Lancet Oncol. – volume: 34 start-page: 3119 year: 2016 end-page: 3125 ident: bib109 article-title: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer publication-title: J. Clin. Oncol. – volume: 28 start-page: 1193 year: 2014 end-page: 1202 ident: bib110 article-title: Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy publication-title: AIDS – volume: 25 start-page: 1564 year: 2019 end-page: 1573 ident: bib8 article-title: Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy publication-title: Clin. Cancer Res. – volume: 5 start-page: 77 year: 2017 ident: bib192 article-title: Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer publication-title: J. Immunother. Cancer – volume: 19 start-page: 2885 year: 2018 ident: bib53 article-title: The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium publication-title: Int. J. Mol. Sci. – volume: 12 start-page: 208 year: 2017 end-page: 222 ident: bib72 article-title: PD-L1 Immunohistochemistry assays for lung cancer: results from Phase 1 of the Blueprint PD-L1 IHC assay comparison project publication-title: J. Thorac. Oncol. – volume: 79 year: 2019 ident: bib130 article-title: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy [abstract]. In Proceedings of the American Association for Cancer Research Annual Meeting 2019 (AACR) publication-title: Cancer Res. – volume: 8 start-page: 1492 year: 2016 end-page: 1504 ident: bib89 article-title: Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) publication-title: Ann. Oncol. – volume: 35 start-page: 785 year: 2017 end-page: 792 ident: bib183 article-title: Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma publication-title: J. Clin. Oncol. – volume: 8 start-page: 2171 year: 2017 end-page: 2186 ident: bib36 article-title: PD-1 and its ligands are important immune checkpoints in cancer publication-title: Oncotarget – volume: 541 start-page: 321 year: 2017 end-page: 330 ident: bib28 article-title: Elements of cancer immunity and the cancer-immune set point publication-title: Nature – volume: 6 start-page: 91 year: 2018 ident: bib138 article-title: Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer publication-title: J. Immunother. Cancer – volume: 6 start-page: 23002 year: 2016 ident: bib122 article-title: Effects of Systemically Administered Hydrocortisone on the Human Immunome publication-title: Sci. Rep. – volume: 51 start-page: 202 year: 2019 end-page: 206 ident: bib151 article-title: Tumor mutational load predicts survival after immunotherapy across multiple cancer types publication-title: Nat. Genet. – volume: 378 start-page: 2093 year: 2018 end-page: 2104 ident: bib68 article-title: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden publication-title: N. Engl. J. Med. – volume: 7 start-page: 387 year: 2019 end-page: 401 ident: bib137 article-title: Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial publication-title: Lancet Respir. Med. – volume: 59 start-page: 410 year: 2018 end-page: 417 ident: bib155 article-title: Immune Modulation Therapy and Imaging: Workshop Report publication-title: J. Nucl. Med. – volume: 12 start-page: 298 year: 2012 end-page: 306 ident: bib47 article-title: The immune contexture in human tumours: impact on clinical outcome publication-title: Nat. Rev. Cancer – year: 2017 ident: bib24 article-title: Meet the Expert: The Cancer-Immune Set Point and the Future of Cancer Immunotherapy – volume: 30 start-page: v851 year: 2019 end-page: v934 ident: bib164 article-title: IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. EMSO 2019 Congress. Ann publication-title: Oncol. – volume: 25 start-page: 1549 year: 2019 end-page: 1559 ident: bib84 article-title: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer publication-title: Nat. Med. – volume: 175 start-page: 998 year: 2018 end-page: 1013.e20 ident: bib148 article-title: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma publication-title: Cell – volume: 18 start-page: 1150 year: 2012 end-page: 1163 ident: bib108 article-title: First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation publication-title: Biol. Blood Marrow Transplant. – volume: 15 start-page: 7412 year: 2009 end-page: 7420 ident: bib184 article-title: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria publication-title: Clin. Cancer Res. – volume: 379 start-page: 2040 year: 2018 end-page: 2051 ident: bib127 article-title: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. – volume: 79 start-page: v253 year: 2019 end-page: v324 ident: bib82 article-title: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. EMSO 2019 Congress publication-title: Cancer Res. – volume: 3 start-page: 243 year: 2013 ident: bib29 article-title: Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors publication-title: Front. Oncol. – volume: 389 start-page: 67 year: 2017 end-page: 76 ident: bib11 article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial publication-title: Lancet – volume: 8 start-page: 285 year: 2018 ident: bib90 article-title: Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy publication-title: Front. Oncol. – volume: 5 start-page: 417 year: 2017 end-page: 424 ident: bib177 article-title: Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC publication-title: Cancer Immunol. Res. – volume: 39 start-page: 1 year: 2013 end-page: 10 ident: bib27 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity – volume: 20 start-page: 999 year: 2019 ident: bib185 article-title: The Contribution of the Immune System in Bone Metastasis Pathogenesis publication-title: Int. J. Mol. Sci. – volume: 19 start-page: 1480 year: 2018 end-page: 1492 ident: bib76 article-title: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol. – volume: 24 start-page: 749 year: 2018 end-page: 757 ident: bib111 article-title: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma publication-title: Nat. Med. – volume: 29 year: 2018 ident: bib21 article-title: 1239TiP MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types publication-title: Ann. Oncol. – volume: 140 start-page: 888 year: 2017 end-page: 899 ident: bib128 article-title: The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration publication-title: Int. J. Cancer – volume: 7 start-page: 188 year: 2017 end-page: 201 ident: bib156 article-title: Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations publication-title: Cancer Discov. – volume: 1 year: 2013 ident: bib23 article-title: Statistical issues and challenges in immuno-oncology publication-title: J. Immunother. Cancer – volume: 36 start-page: 850 year: 2018 end-page: 858 ident: bib75 article-title: Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy publication-title: J. Clin. Oncol. – volume: 22 start-page: 1865 year: 2016 end-page: 1874 ident: bib66 article-title: The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition publication-title: Clin. Cancer Res. – volume: 19 start-page: 215 year: 2019 end-page: 227 ident: bib150 article-title: Host tissue determinants of tumour immunity publication-title: Nat. Rev. Cancer – volume: 122 start-page: 899 year: 2012 end-page: 910 ident: bib149 article-title: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors publication-title: J. Clin. Invest. – volume: 7 start-page: 387 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib137 article-title: Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(19)30084-0 – volume: 48 start-page: 812 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib170 article-title: The Immune Landscape of Cancer publication-title: Immunity doi: 10.1016/j.immuni.2018.03.023 – volume: 5 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib39 article-title: Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection publication-title: JCI Insight – volume: 19 start-page: 2885 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib53 article-title: The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms19102885 – volume: 22 start-page: 886 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib46 article-title: Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1136 – volume: 25 start-page: 1549 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib84 article-title: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer publication-title: Nat. Med. doi: 10.1038/s41591-019-0592-2 – volume: 165 start-page: 35 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib80 article-title: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma publication-title: Cell doi: 10.1016/j.cell.2016.02.065 – volume: 22 start-page: 3286 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib10 article-title: A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-15-1696 – volume: 25 start-page: 89 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib152 article-title: Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers publication-title: Nat. Med. doi: 10.1038/s41591-018-0266-5 – volume: 19 start-page: 1468 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib14 article-title: Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30673-9 – volume: 376 start-page: 836 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib87 article-title: Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1609783 – volume: 129 start-page: 1039 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib30 article-title: PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR publication-title: Blood doi: 10.1182/blood-2016-09-738245 – volume: 12 start-page: 61 year: 2011 ident: 10.1016/j.immuni.2019.12.011_bib37 article-title: Experimental mouse tumour models: what can be learnt about human cancer immunology? publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3129 – volume: 169 start-page: 750 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib94 article-title: Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses publication-title: Cell doi: 10.1016/j.cell.2017.04.014 – volume: 5 start-page: 77 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib192 article-title: Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer publication-title: J. Immunother. Cancer doi: 10.1186/s40425-017-0278-6 – volume: 21 start-page: 431 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib56 article-title: Translational value of mouse models in oncology drug development publication-title: Nat. Med. doi: 10.1038/nm.3853 – volume: 175 start-page: 998 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib148 article-title: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma publication-title: Cell doi: 10.1016/j.cell.2018.10.038 – volume: 39 start-page: 1 year: 2013 ident: 10.1016/j.immuni.2019.12.011_bib27 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – volume: 21 start-page: 543 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib22 article-title: Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers publication-title: J. Med. Econ. doi: 10.1080/13696998.2017.1423488 – volume: 115 start-page: 98 year: 2005 ident: 10.1016/j.immuni.2019.12.011_bib77 article-title: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct publication-title: Int. J. Cancer doi: 10.1002/ijc.20908 – volume: 121 start-page: 4322 year: 2011 ident: 10.1016/j.immuni.2019.12.011_bib178 article-title: A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis publication-title: J. Clin. Invest. doi: 10.1172/JCI58653 – volume: 24 start-page: 1441 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib49 article-title: Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab publication-title: Nat. Med. doi: 10.1038/s41591-018-0134-3 – volume: 5 start-page: 357 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib181 article-title: Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0287 – volume: 378 start-page: 1277 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib118 article-title: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1712126 – volume: 378 start-page: 2078 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib50 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801005 – volume: 5 start-page: 524 year: 2004 ident: 10.1016/j.immuni.2019.12.011_bib135 article-title: T cell killing does not require the formation of a stable mature immunological synapse publication-title: Nat. Immunol. doi: 10.1038/ni1058 – volume: 24 start-page: 978 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib61 article-title: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing publication-title: Nat. Med. doi: 10.1038/s41591-018-0045-3 – volume: 69 start-page: 319 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib169 article-title: Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology publication-title: Annu. Rev. Med. doi: 10.1146/annurev-med-062016-050343 – volume: 36 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib85 article-title: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC publication-title: J. Clin. Ontol. – volume: 44 start-page: 609 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib38 article-title: MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade publication-title: Immunity doi: 10.1016/j.immuni.2016.01.024 – volume: 35 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib141 article-title: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC) publication-title: J. Clin. Ontol. – volume: 35 start-page: 785 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib183 article-title: Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.66.1389 – volume: 12 start-page: 298 year: 2012 ident: 10.1016/j.immuni.2019.12.011_bib47 article-title: The immune contexture in human tumours: impact on clinical outcome publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3245 – volume: 18 start-page: 197 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib48 article-title: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0007-y – volume: 365 start-page: 725 year: 2011 ident: 10.1016/j.immuni.2019.12.011_bib132 article-title: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1103849 – volume: 36 start-page: 850 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib75 article-title: Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.75.1644 – volume: 15 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib20 article-title: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma publication-title: BMC Genomics doi: 10.1186/1471-2164-15-190 – volume: 28 start-page: 1193 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib110 article-title: Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy publication-title: AIDS doi: 10.1097/QAD.0000000000000243 – volume: 30 start-page: v851 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib131 article-title: Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz394.075 – volume: 174 start-page: 1293 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib9 article-title: Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment publication-title: Cell doi: 10.1016/j.cell.2018.05.060 – volume: 122 start-page: 899 year: 2012 ident: 10.1016/j.immuni.2019.12.011_bib149 article-title: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors publication-title: J. Clin. Invest. doi: 10.1172/JCI45817 – volume: 7 start-page: 316 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib93 article-title: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0793-8 – volume: 18 start-page: 175 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib140 article-title: Delivery technologies for cancer immunotherapy publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0006-z – volume: 25 start-page: 946 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib52 article-title: Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0793 – volume: 4 start-page: 279 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib115 article-title: De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0045 – volume: 348 start-page: 124 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib143 article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer publication-title: Science doi: 10.1126/science.aaa1348 – volume: 34 start-page: 3119 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib109 article-title: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.67.9761 – volume: 5 start-page: 181 year: 2008 ident: 10.1016/j.immuni.2019.12.011_bib188 article-title: Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine publication-title: Clin. Trials doi: 10.1177/1740774508091815 – volume: 36 start-page: 477 year: 2013 ident: 10.1016/j.immuni.2019.12.011_bib97 article-title: Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy publication-title: J. Immunother. doi: 10.1097/01.cji.0000436722.46675.4a – volume: 131 start-page: 1522 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib55 article-title: Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia publication-title: Blood doi: 10.1182/blood-2017-08-798322 – volume: 24 start-page: 193 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib26 article-title: Combinations of Bevacizumab With Cancer Immunotherapy publication-title: Cancer J. doi: 10.1097/PPO.0000000000000327 – volume: 8 start-page: 2171 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib36 article-title: PD-1 and its ligands are important immune checkpoints in cancer publication-title: Oncotarget doi: 10.18632/oncotarget.13895 – volume: 6 start-page: 91 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib138 article-title: Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0409-8 – volume: 524 start-page: 47 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib54 article-title: Comprehensive genomic profiles of small cell lung cancer publication-title: Nature doi: 10.1038/nature14664 – volume: 59 start-page: 410 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib155 article-title: Immune Modulation Therapy and Imaging: Workshop Report publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.195610 – volume: 7 start-page: 264 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib2 article-title: Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-0828 – volume: 127 start-page: 2930 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib7 article-title: IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade publication-title: J. Clin. Invest. doi: 10.1172/JCI91190 – volume: 101 start-page: 114 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib103 article-title: Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2018.06.033 – volume: 29 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib117 article-title: LBA6_PRJAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy424.036 – volume: 18 start-page: e143 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib154 article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30074-8 – volume: 34 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib194 article-title: Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.e20665 – volume: 375 start-page: 2255 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib173 article-title: T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1609279 – volume: 7 start-page: 65 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib18 article-title: Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0540-1 – volume: 515 start-page: 568 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib176 article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance publication-title: Nature doi: 10.1038/nature13954 – volume: 79 start-page: v253 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib82 article-title: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. EMSO 2019 Congress publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2019-CT061 – volume: 271 start-page: 1734 year: 1996 ident: 10.1016/j.immuni.2019.12.011_bib96 article-title: Enhancement of antitumor immunity by CTLA-4 blockade publication-title: Science doi: 10.1126/science.271.5256.1734 – volume: 362 start-page: eaar3593 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib33 article-title: Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy publication-title: Science doi: 10.1126/science.aar3593 – volume: 8 start-page: 147 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib101 article-title: Estimation of treatment effects in weighted log-rank tests publication-title: Contemp. Clin. Trials Commun. doi: 10.1016/j.conctc.2017.09.004 – volume: 34 start-page: 1510 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib74 article-title: Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.64.0391 – volume: 7 start-page: 188 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib156 article-title: Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1223 – volume: 103 start-page: 259 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib160 article-title: The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2018.07.127 – volume: 25 start-page: 1564 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib8 article-title: Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-1316 – volume: 387 start-page: 1909 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib146 article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00561-4 – volume: 18 start-page: 1150 year: 2012 ident: 10.1016/j.immuni.2019.12.011_bib108 article-title: First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation publication-title: Biol. Blood Marrow Transplant. doi: 10.1016/j.bbmt.2012.04.005 – volume: 17 start-page: 99 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib15 article-title: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab publication-title: J. Transl. Med. doi: 10.1186/s12967-019-1847-x – volume: 8 start-page: 285 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib90 article-title: Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy publication-title: Front. Oncol. doi: 10.3389/fonc.2018.00285 – volume: 14 start-page: 491 year: 1993 ident: 10.1016/j.immuni.2019.12.011_bib51 article-title: Natural history of HLA expression during tumour development publication-title: Immunol. Today doi: 10.1016/0167-5699(93)90264-L – volume: 68 start-page: 394 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib16 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21492 – volume: 118 start-page: 1099 year: 2008 ident: 10.1016/j.immuni.2019.12.011_bib167 article-title: Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells publication-title: J. Clin. Invest. doi: 10.1172/JCI34409C1 – volume: 160 start-page: 1224 year: 1998 ident: 10.1016/j.immuni.2019.12.011_bib123 article-title: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells publication-title: J. Immunol. doi: 10.4049/jimmunol.160.3.1224 – volume: 387 start-page: 1540 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib70 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 24 start-page: 3292 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib31 article-title: A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-17-3662 – volume: 28 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib5 article-title: Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC) publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx302.003 – volume: 140 start-page: 317 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib105 article-title: Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma publication-title: J. Neurooncol. doi: 10.1007/s11060-018-2955-9 – volume: 15 start-page: 777 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib119 article-title: Accelerating anticancer drug development - opportunities and trade-offs publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-018-0102-3 – volume: 60 start-page: 2109 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib32 article-title: Immune tolerance in liver disease publication-title: Hepatology doi: 10.1002/hep.27254 – volume: 36 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib63 article-title: 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.9516 – volume: 541 start-page: 321 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib28 article-title: Elements of cancer immunity and the cancer-immune set point publication-title: Nature doi: 10.1038/nature21349 – volume: 93 start-page: 9730 year: 1996 ident: 10.1016/j.immuni.2019.12.011_bib79 article-title: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.93.18.9730 – volume: 523 start-page: 231 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib193 article-title: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity publication-title: Nature doi: 10.1038/nature14404 – volume: 3 start-page: 121522 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib124 article-title: Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma publication-title: JCI Insight doi: 10.1172/jci.insight.121522 – volume: 29 start-page: x39 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib144 article-title: LBA6 Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. ESMO Immuno-Oncology Congress 2018Ann publication-title: Oncol. – volume: 1 year: 2013 ident: 10.1016/j.immuni.2019.12.011_bib23 article-title: Statistical issues and challenges in immuno-oncology publication-title: J. Immunother. Cancer – volume: 257 start-page: 72 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib102 article-title: TCR repertoires of intratumoral T-cell subsets publication-title: Immunol. Rev. doi: 10.1111/imr.12140 – volume: 29 start-page: 1807 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib65 article-title: Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy232 – volume: 9 start-page: 137 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib88 article-title: Genetically engineered mouse models in oncology research and cancer medicine publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201606857 – volume: 140 start-page: 888 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib128 article-title: The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration publication-title: Int. J. Cancer doi: 10.1002/ijc.30489 – volume: 378 start-page: 2093 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib68 article-title: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801946 – volume: 13 start-page: 1733 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib163 article-title: FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2018.05.004 – volume: 28 start-page: iv119 issue: suppl_4 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib62 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx225 – volume: 389 start-page: 67 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib11 article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32455-2 – volume: 171 start-page: 1259 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib114 article-title: Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution publication-title: Cell doi: 10.1016/j.cell.2017.10.001 – volume: 79 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib130 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2019-1267 – volume: 4 start-page: 845 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib78 article-title: Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0060 – volume: 169 start-page: 1342 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib187 article-title: Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing publication-title: Cell doi: 10.1016/j.cell.2017.05.035 – volume: 21 start-page: 1019 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib145 article-title: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2708 – volume: 376 start-page: 2109 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib83 article-title: Tracking the Evolution of Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1616288 – volume: 34 start-page: 1 year: 2010 ident: 10.1016/j.immuni.2019.12.011_bib171 article-title: Immune tolerance: what is unique about the liver publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2009.08.008 – volume: 10 start-page: 4186 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib59 article-title: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma publication-title: Nat. Commun. doi: 10.1038/s41467-019-12160-2 – volume: 377 start-page: 2531 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib120 article-title: Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1707447 – volume: 29 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib21 article-title: 1239TiP MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy288.110 – volume: 100 start-page: 14145 year: 2003 ident: 10.1016/j.immuni.2019.12.011_bib43 article-title: Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.2334336100 – volume: 52 start-page: 117 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib67 article-title: Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2017.12.002 – volume: 200 start-page: 400 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib166 article-title: Metabolic Barriers to T Cell Function in Tumors publication-title: J. Immunol. doi: 10.4049/jimmunol.1701041 – volume: 16 start-page: e307 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib19 article-title: Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution publication-title: Clin. Genitourin. Cancer doi: 10.1016/j.clgc.2017.10.008 – volume: 24 start-page: 36 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib182 article-title: Toxicities Associated With PD-1/PD-L1 Blockade publication-title: Cancer J. doi: 10.1097/PPO.0000000000000296 – volume: 30 start-page: v851 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib164 article-title: IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. EMSO 2019 Congress. Ann publication-title: Oncol. – volume: 351 start-page: 1463 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib113 article-title: Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade publication-title: Science doi: 10.1126/science.aaf1490 – volume: 132 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib153 article-title: Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel publication-title: Blood – volume: 9 start-page: 70 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib121 article-title: Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.00070 – volume: 167 start-page: 671 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib35 article-title: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-017-4537-5 – volume: 554 start-page: 544 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib107 article-title: TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells publication-title: Nature doi: 10.1038/nature25501 – volume: 10 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib162 article-title: Clinical assessment of immune-related adverse events publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/1758835918764628 – volume: 29 start-page: 84 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib168 article-title: Comprehensive analysis of the clinical immuno-oncology landscape publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx755 – volume: 51 start-page: 202 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib151 article-title: Tumor mutational load predicts survival after immunotherapy across multiple cancer types publication-title: Nat. Genet. doi: 10.1038/s41588-018-0312-8 – volume: 5 start-page: 29 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib116 article-title: Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0114 – volume: 22 start-page: 1865 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib66 article-title: The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1507 – volume: 15 start-page: 3077 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib133 article-title: Macrophage Susceptibility to Emactuzumab (RG7155) Treatment publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0157 – volume: 6 start-page: 23002 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib122 article-title: Effects of Systemically Administered Hydrocortisone on the Human Immunome publication-title: Sci. Rep. doi: 10.1038/srep23002 – volume: 40 start-page: 24 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib190 article-title: Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2016.02.006 – volume: 2 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib165 article-title: Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment publication-title: J. Immunother. Cancer – volume: 359 start-page: 1361 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib86 article-title: CAR T cell immunotherapy for human cancer publication-title: Science doi: 10.1126/science.aar6711 – volume: 375 start-page: 819 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib186 article-title: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1604958 – volume: 13 start-page: 1302 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib174 article-title: PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project publication-title: J. Thorac Oncol. doi: 10.1016/j.jtho.2018.05.013 – volume: 15 start-page: 7412 year: 2009 ident: 10.1016/j.immuni.2019.12.011_bib184 article-title: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-1624 – volume: 23 start-page: 3203 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib129 article-title: Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-16-1946-T – volume: 8 start-page: 1492 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib89 article-title: Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw217 – volume: 515 start-page: 563 year: 2014 ident: 10.1016/j.immuni.2019.12.011_bib69 article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients publication-title: Nature doi: 10.1038/nature14011 – volume: 24 start-page: 749 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib111 article-title: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma publication-title: Nat. Med. doi: 10.1038/s41591-018-0053-3 – volume: 777 start-page: 1 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib126 article-title: Multiclonal tumor origin: Evidence and implications publication-title: Mutat. Res. doi: 10.1016/j.mrrev.2018.05.001 – volume: 8 start-page: 730 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib58 article-title: Genetic Mechanisms of Immune Evasion in Colorectal Cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1327 – volume: 3 start-page: 243 year: 2013 ident: 10.1016/j.immuni.2019.12.011_bib29 article-title: Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors publication-title: Front. Oncol. doi: 10.3389/fonc.2013.00243 – volume: 128 start-page: 4804 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib161 article-title: Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma publication-title: J. Clin. Invest. doi: 10.1172/JCI121476 – year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib24 – volume: 11 start-page: eaax8861 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib100 article-title: CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aax8861 – volume: 377 start-page: 1409 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib99 article-title: First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication publication-title: N. Engl. J. Med. doi: 10.1056/NEJMp1709968 – volume: 19 start-page: 1480 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib76 article-title: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30700-9 – volume: 86 start-page: 97 year: 2009 ident: 10.1016/j.immuni.2019.12.011_bib13 article-title: I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2009.68 – year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib57 – volume: 35 start-page: 871 year: 2011 ident: 10.1016/j.immuni.2019.12.011_bib180 article-title: The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation publication-title: Immunity doi: 10.1016/j.immuni.2011.09.021 – volume: 12 start-page: 208 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib72 article-title: PD-L1 Immunohistochemistry assays for lung cancer: results from Phase 1 of the Blueprint PD-L1 IHC assay comparison project publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.2228 – volume: 372 start-page: 2509 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib95 article-title: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1500596 – volume: 500 start-page: 415 year: 2013 ident: 10.1016/j.immuni.2019.12.011_bib1 article-title: Signatures of mutational processes in human cancer publication-title: Nature doi: 10.1038/nature12477 – volume: 5 start-page: 417 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib177 article-title: Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0325 – volume: 51 start-page: 123 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib4 article-title: The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2018.03.006 – volume: 368 start-page: 1509 year: 2013 ident: 10.1016/j.immuni.2019.12.011_bib60 article-title: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1215134 – volume: 16 start-page: 759 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib191 article-title: Mouse models in oncoimmunology publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.91 – volume: 35 start-page: 673 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib73 article-title: Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.35.4_suppl.673 – volume: 5 start-page: 755 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib157 article-title: Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-17-0292 – volume: 553 start-page: 347 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib42 article-title: High response rate to PD-1 blockade in desmoplastic melanomas publication-title: Nature doi: 10.1038/nature25187 – volume: 389 start-page: 255 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib142 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X – volume: 88 start-page: 100 year: 1996 ident: 10.1016/j.immuni.2019.12.011_bib139 article-title: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/88.2.100 – volume: 16 start-page: 57 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib172 article-title: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)71170-2 – volume: 376 start-page: 2415 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib17 article-title: First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1613493 – volume: 20 start-page: 1083 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib104 article-title: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30274-8 – volume: 321 start-page: 974 year: 2008 ident: 10.1016/j.immuni.2019.12.011_bib12 article-title: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody publication-title: Science doi: 10.1126/science.1158545 – volume: 102 start-page: 934 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib158 article-title: Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials publication-title: Clin. Pharmacol. Ther. doi: 10.1002/cpt.814 – volume: 377 start-page: 1919 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib3 article-title: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709937 – volume: 115 start-page: E10119 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib92 article-title: Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1802166115 – volume: 19 start-page: 215 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib150 article-title: Host tissue determinants of tumour immunity publication-title: Nat. Rev. Cancer – volume: 28 start-page: mdx380.017 year: 2017 ident: 10.1016/j.immuni.2019.12.011_bib179 article-title: 1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx380.017 – volume: 557 start-page: 575 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib159 article-title: Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates publication-title: Nature doi: 10.1038/s41586-018-0130-2 – volume: 8 start-page: 111 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib91 article-title: Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-015-0213-6 – volume: 20 start-page: 999 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib185 article-title: The Contribution of the Immune System in Bone Metastasis Pathogenesis publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20040999 – volume: 20 start-page: 849 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib41 article-title: Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30027-0 – volume: 379 start-page: 2040 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib127 article-title: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1810865 – volume: 9 start-page: 32 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib40 article-title: Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution publication-title: Nat. Commun doi: 10.1038/s41467-017-02424-0 – volume: 567 start-page: 479 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib147 article-title: Neoantigen-directed immune escape in lung cancer evolution publication-title: Nature doi: 10.1038/s41586-019-1032-7 – volume: 27 start-page: 15 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib112 article-title: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.12.001 – volume: 108 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib81 article-title: Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djw144 – volume: 22 start-page: 4711 year: 2004 ident: 10.1016/j.immuni.2019.12.011_bib34 article-title: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2004.04.020 – volume: 36 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib6 article-title: Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC) publication-title: Journal of Clinial Onocology – volume: 25 start-page: 6061 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib64 article-title: Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-3488 – volume: 50 start-page: 403 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib189 article-title: Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis publication-title: Immunity doi: 10.1016/j.immuni.2018.12.024 – volume: 61 start-page: 61 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib44 article-title: Oncogenic viruses: Lessons learned using next-generation sequencing technologies publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2016.03.086 – volume: 8 start-page: 395 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib125 article-title: Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1320 – volume: 33 start-page: 2938 year: 2015 ident: 10.1016/j.immuni.2019.12.011_bib134 article-title: Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.59.1636 – volume: 6 start-page: 108 year: 2018 ident: 10.1016/j.immuni.2019.12.011_bib175 article-title: Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0426-7 – volume: 30 start-page: v851 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib98 article-title: Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, hepatocellular carcinoma (HCC). ESMO 2019 Congress publication-title: Ann. Oncol. – volume: 192 start-page: 1027 year: 2000 ident: 10.1016/j.immuni.2019.12.011_bib45 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. doi: 10.1084/jem.192.7.1027 – volume: 375 start-page: 1823 year: 2016 ident: 10.1016/j.immuni.2019.12.011_bib136 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606774 – volume: 30 start-page: v475 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib106 article-title: Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. ESMO 2019 Congress publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz253.018 – volume: 30 start-page: v851 year: 2019 ident: 10.1016/j.immuni.2019.12.011_bib71 article-title: Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and –042 trials publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz394.077
SSID	ssj0014590
Score	2.7278466
SecondaryResourceType	review_article
Snippet	Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation... SummaryCancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	17
SubjectTerms	adaptive immune resistance Antigens Biology biomarkers bispecific antibodies Cancer cancer immune phenotypes Cancer immunotherapy CAR T cellular therapy Clinical trials Collaboration Cytotoxicity Drug dosages Humans Immune system immuno-oncology Immunology Immunotherapy Immunotherapy - methods intrinsic immune resistance Models, Biological Mutation Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy Patients primary immune escape secondary immune escape synthetic immunity T cell engagers Tumor Microenvironment - immunology tumor mutational burden Tumors
Title	Top 10 Challenges in Cancer Immunotherapy
URI	https://dx.doi.org/10.1016/j.immuni.2019.12.011 https://www.ncbi.nlm.nih.gov/pubmed/31940268 https://www.proquest.com/docview/2337925233 https://www.proquest.com/docview/2339792485
Volume	52
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwED9EUXwRv51OqeCLD2Ftk7TJ4xwOP9AH3XBvYU1TmEg35nzYf-8lTQs-jIFvpb3A8bvL5a65D4CbNA9RylITY3RGGCsoEVJEJE1MXgiDIndNXF9ek4chexrx0Qb06loYm1bpbX9l05219m86Hs3ObDLpvNtUQgzCUYdQZ6kr-KVMuCK-0V1zk8C4DJu8Q6Suy-dcjtfE1WDYBC_pfgpG0arjaZX76Y6h_j7sef8x6FYsHsCGKQ9hu5oouTyEnRd_V34Et4PpLIjCoFePS_kOJmXQs1KeB4-WJV98tTyGYf9-0HsgfjAC0YwmC2LiFN2kghvENtcyo6nJ0HMqZMi1yA1F7RCFiTXXcYqfxlmY4wPldrSwzHlKT2CznJbmDIJYci3HMrFtwJhIGMbKnDJJOR5aeVHoFtAaD6V913A7vOJL1elhn6pCUVkUVRQrRLEFpFk1q7pmrKFPa6jVH-krNOxrVrZrySi_-75VTGkqYwyxaQuum8-4b-xlyLg00x9HI5GICd6C00qiDauoUhhWJ-L832xdwG5sA_MwIhFrw-Zi_mMu0XtZZFew1X1--3i-cmr6C4wK6pg
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Na9swFH-0Hf24jK3d1mzd5sJ26EHE1oclHXbYsoWkaXppCrlpsSxDxnBCk1Lyd_Uf7JMtG3YohUFvxpbM4_eent6T3gfAF5nHyGVtiXM2I5wXjCitEiJTlxfKIcurIq7jy3Rwzc-nYroF900ujA-rDLq_1umVtg5vugHN7nI-7175UEJ0wlGGUGZZrEJk5cht7tBvW30b_kQmf6W0_2vSG5DQWoBYztI1cVSioVEIh9TlVmdMugxtj0LHwqrcMcRXFY5aYanET7MszvGBCd-cV-dCMvzvNrxA60N6bTCc_mivLrjQcRvoiOQ1-XpVUNm8SvrwEWW6OoVMksf2w8fs3Wrf67-Cl8Fgjb7XmLyGLVcewm7dwnJzCHvjcDl_BGeTxTJK4qjX9GdZRfMy6nmxuomGnqSQ7bV5A9fPAtdb2CkXpTuGiGph9Uynvu4YVylH51wwrpnAXTIvCtsB1uBhbChT7rtl_DVNPNofU6NoPIomoQZR7ABpZy3rMh1PjJcN1OYfcTO4kzwx86ThjAnLfWUoY1JT9OlZB07bz7hQ_e3LrHSL22qMxkFciQ68qznakooyjH58qt7_N1mfYX8wGV-Yi-Hl6AMcUH8qECck4Sews765dR_RdFpnnypRjeD3c6-NB5Y9Ju4
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Top+10+Challenges+in+Cancer+Immunotherapy&rft.jtitle=Immunity+%28Cambridge%2C+Mass.%29&rft.au=Hegde%2C+Priti+S.&rft.au=Chen%2C+Daniel+S.&rft.date=2020-01-14&rft.pub=Elsevier+Inc&rft.issn=1074-7613&rft.eissn=1097-4180&rft.volume=52&rft.issue=1&rft.spage=17&rft.epage=35&rft_id=info:doi/10.1016%2Fj.immuni.2019.12.011&rft.externalDocID=S1074761319305308
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1074-7613&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1074-7613&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1074-7613&client=summon